{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T22:30:34Z","timestamp":1785537034935,"version":"3.56.0"},"reference-count":214,"publisher":"Bentham Science Publishers Ltd.","issue":"5","funder":[{"DOI":"10.13039\/100000738","name":"Department of Veterans Affairs, Veterans Health Administration, Office of Research and Development, Rehabilitation Research and Development","doi-asserted-by":"publisher","award":["RX000889"],"award-info":[{"award-number":["RX000889"]}],"id":[{"id":"10.13039\/100000738","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000062","name":"National Institute of Diabetes and Digestive and Kidney Diseases from NIH","doi-asserted-by":"publisher","award":["DK107339"],"award-info":[{"award-number":["DK107339"]}],"id":[{"id":"10.13039\/100000062","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["eurekaselect.com"],"crossmark-restriction":true},"short-container-title":["CDR"],"published-print":{"date-parts":[[2022,6]]},"abstract":"<jats:sec><jats:title>Introduction:<\/jats:title><jats:p>Animal models have been widely used to investigate the etiology and potential treatments for diabetic peripheral neuropathy. What we have learned from these studies and the extent to which this information has been adapted for the human condition will be the subject of this review article.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods:<\/jats:title><jats:p>A comprehensive search of the PubMed database was performed, and relevant articles on the topic were included in this review.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results:<\/jats:title><jats:p>Extensive study of diabetic animal models has shown that the etiology of diabetic peripheral neuropathy is complex, with multiple mechanisms affecting neurons, Schwann cells, and the microvasculature, which contribute to the phenotypic nature of this most common complication of diabetes. Moreover, animal studies have demonstrated that the mechanisms related to peripheral neuropathy occurring in type 1 and type 2 diabetes are likely different, with hyperglycemia being the primary factor for neuropathology in type 1 diabetes, which contributes to a lesser extent in type 2 diabetes, whereas insulin resistance, hyperlipidemia, and other factors may have a greater role. Two of the earliest mechanisms described from animal studies as a cause for diabetic peripheral neuropathy were the activation of the aldose reductase pathway and increased non-enzymatic glycation. However, continuing research has identified numerous other potential factors that may contribute to diabetic peripheral neuropathy, including oxidative and inflammatory stress, dysregulation of protein kinase C and hexosamine pathways, and decreased neurotrophic support. In addition, recent studies have demonstrated that peripheral neuropathy-like symptoms are present in animal models, representing pre-diabetes in the absence of hyperglycemia.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions:<\/jats:title><jats:p>This complexity complicates the successful treatment of diabetic peripheral neuropathy, and results in the poor outcome of translating successful treatments from animal studies to human clinical trials.<\/jats:p><\/jats:sec>","DOI":"10.2174\/1573399817666210504101609","type":"journal-article","created":{"date-parts":[[2021,5,5]],"date-time":"2021-05-05T16:11:49Z","timestamp":1620231109000},"update-policy":"https:\/\/doi.org\/10.2174\/bsp_crossmark_policy","source":"Crossref","is-referenced-by-count":22,"title":["Treatment for Diabetic Peripheral Neuropathy: What have we Learned from Animal Models?"],"prefix":"10.2174","volume":"18","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7737-5554","authenticated-orcid":true,"given":"Mark","family":"Yorek","sequence":"first","affiliation":[{"name":"Department of Internal Medicine, University of Iowa, Iowa City, IA, 52242 USA | Department of Veterans Affairs Iowa City Health Care System, Iowa City, IA, 52246 USA | Fraternal Order of Eagles Diabetes Research Center, University of Iowa, Iowa City, IA, 52242 USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"965","reference":[{"key":"ref=1","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1016\/j.tins.2013.04.008","volume":"36","author":"Zenker J.","year":"2013","unstructured":"Zenker J.; Ziegler D.; Chrast R.; Novel pathogenic pathways in diabetic neuropathy. Trends Neurosci 2013,36(8),439-449","journal-title":"Trends Neurosci"},{"key":"ref=2","doi-asserted-by":"publisher","first-page":"1455","DOI":"10.1056\/NEJMcp1503948","volume":"374","author":"Vinik A.I.","year":"2016","unstructured":"Vinik A.I.; Clinical practice. diabetic sensory and motor neuropathy. N Engl J Med 2016,374(15),1455-1464","journal-title":"N Engl J Med"},{"key":"ref=3","doi-asserted-by":"publisher","first-page":"136","DOI":"10.2337\/dc16-2042","volume":"40","author":"Pop-Busui R.","year":"2017","unstructured":"Pop-Busui R.; Boulton A.J.; Feldman E.L.; Bril V.; Freeman R.; Malik R.A.; Sosenko J.M.; Ziegler D.; Diabetic neuropathy: a position statement by the American Diabetes Association. Diabetes Care 2017,40(1),136-154","journal-title":"Diabetes Care"},{"key":"ref=4","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1016\/B978-0-444-53480-4.00018-7","volume":"126","author":"Perkins B.","year":"2014","unstructured":"Perkins B.; Bril V.; Electrophysiologic testing in diabetic neuropathy. Handb Clin Neurol 2014,126,235-248","journal-title":"Handb Clin Neurol"},{"key":"ref=5","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1038\/s41572-019-0092-1","volume":"5","author":"Feldman E.L.","year":"2019","unstructured":"Feldman E.L.; Callaghan B.C.; Pop-Busui R.; Zochodne D.W.; Wright D.E.; Bennett D.L.; Bril V.; Russell J.W.; Viswanathan V.; Diabetic neuropathy. Nat Rev Dis Primers 2019,5(1),41","journal-title":"Nat Rev Dis Primers"},{"key":"ref=6","doi-asserted-by":"publisher","first-page":"1239","DOI":"10.1111\/jdi.12833","volume":"9","author":"Kobayashi M.","year":"2018","unstructured":"Kobayashi M.; Zochodne D.W.; Diabetic neuropathy and the sensory neuron: New aspects of pathogenesis and their treatment implications. J Diabetes Investig 2018,9(6),1239-1254","journal-title":"J Diabetes Investig"},{"key":"ref=7","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1016\/B978-0-444-53480-4.00030-8","volume":"126","author":"Wilson N.M.","year":"2014","unstructured":"Wilson N.M.; Wright D.E.; Experimental motor neuropathy in diabetes. Handb Clin Neurol 2014,126,461-467","journal-title":"Handb Clin Neurol"},{"key":"ref=8","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1177\/1073858408316175","volume":"14","author":"Zochodne D.W.","year":"2008","unstructured":"Zochodne D.W.; Ramji N.; Toth C.; Neuronal targeting in diabetes mellitus: a story of sensory neurons and motor neurons. Neuroscientist 2008,14(4),311-318","journal-title":"Neuroscientist"},{"key":"ref=9","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1007\/s11916-008-0034-1","volume":"12","author":"Tavakoli M.","year":"2008","unstructured":"Tavakoli M.; Mojaddidi M.; Fadavi H.; Malik R.A.; Pathophysiology and treatment of painful diabetic neuropathy. Curr Pain Headache Rep 2008,12(3),192-197","journal-title":"Curr Pain Headache Rep"},{"key":"ref=10","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1097\/NRL.0b013e31815a3956","volume":"14","author":"Smith A.G.","year":"2008","unstructured":"Smith A.G.; Singleton J.R.; Impaired glucose tolerance and neuropathy. Neurologist 2008,14(1),23-29","journal-title":"Neurologist"},{"key":"ref=11","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1002\/mus.20785","volume":"36","author":"Zochodne D.W.","year":"2007","unstructured":"Zochodne D.W.; Diabetes mellitus and the peripheral nervous system: manifestations and mechanisms. Muscle Nerve 2007,36(2),144-166","journal-title":"Muscle Nerve"},{"key":"ref=12","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1016\/bs.irn.2016.03.008","volume":"127","author":"Malik R.A.","year":"2016","unstructured":"Malik R.A.; Wherefore art thou, O treatment for diabetic neuropathy? Int Rev Neurobiol 2016,127,287-317","journal-title":"Int Rev Neurobiol"},{"key":"ref=13","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1007\/s11910-014-0473-5","volume":"14","author":"Albers J.W.","year":"2014","unstructured":"Albers J.W.; Pop-Busui R.; Diabetic neuropathy: mechanisms, emerging treatments, and subtypes. Curr Neurol Neurosci Rep 2014,14(8),473-483","journal-title":"Curr Neurol Neurosci Rep"},{"key":"ref=14","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1016\/S1474-4422(12)70065-0","volume":"11","author":"Callaghan B.C.","year":"2012","unstructured":"Callaghan B.C.; Cheng H.T.; Stables C.L.; Smith A.L.; Feldman E.L.; Diabetic neuropathy: clinical manifestations and current treatments. Lancet Neurol 2012,11(6),521-534","journal-title":"Lancet Neurol"},{"key":"ref=15","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1055\/s-0035-1558972","volume":"35","author":"Izenberg A.","year":"2015","unstructured":"Izenberg A.; Perkins B.A.; Bril V.; Diabetic Neuropathies. Semin Neurol 2015,35(4),424-430","journal-title":"Semin Neurol"},{"key":"ref=16","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1900\/RDS.2015.12.63","volume":"12","author":"Javed S.","year":"2015","unstructured":"Javed S.; Alam U.; Malik R.A.; Treating diabetic neuropathy: present strategies and emerging solutions. Rev Diabet Stud 2015,12(1-2),63-83","journal-title":"Rev Diabet Stud"},{"key":"ref=17","doi-asserted-by":"publisher","first-page":"e0212574","DOI":"10.1371\/journal.pone.0212574","volume":"14","author":"Liu X.","year":"2019","unstructured":"Liu X.; Xu Y.; An M.; Zeng Q.; The risk factors for diabetic peripheral neuropathy: A meta-analysis. PLoS One 2019,14(2),e0212574","journal-title":"PLoS One"},{"key":"ref=18","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1038\/nrd2476","volume":"8","author":"Calcutt N.A.","year":"2009","unstructured":"Calcutt N.A.; Cooper M.E.; Kern T.S.; Schmidt A.M.; Therapies for hyperglycaemia-induced diabetic complications: from animal models to clinical trials. Nat Rev Drug Discov 2009,8(5),417-429","journal-title":"Nat Rev Drug Discov"},{"key":"ref=19","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1002\/cpmo.11","volume":"6","author":"Jolivalt C.G.","year":"2016","unstructured":"Jolivalt C.G.; Frizzi K.E.; Guernsey L.; Marquez A.; Ochoa J.; Rodriguez M.; Calcutt N.A.; Peripheral neuropathy in mouse models of diabetes. Curr Protoc Mouse Biol 2016,6(3),223-255","journal-title":"Curr Protoc Mouse Biol"},{"key":"ref=20","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1093\/ilar\/ilt052","volume":"54","author":"O\u2019Brien P.D.","year":"2014","unstructured":"O\u2019Brien P.D.; Sakowski S.A.; Feldman E.L.; Mouse models of diabetic neuropathy. ILAR J 2014,54(3),259-272","journal-title":"ILAR J"},{"key":"ref=21","doi-asserted-by":"publisher","first-page":"149452","DOI":"10.1155\/2013\/149452","volume":"2013","author":"Islam M.S.","year":"2013","unstructured":"Islam M.S.; Animal models of diabetic neuropathy: progress since 1960s. J Diabetes Res 2013,2013,149452","journal-title":"J Diabetes Res"},{"key":"ref=22","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1016\/bs.irn.2016.03.002","volume":"127","author":"Yorek M.A.","year":"2016","unstructured":"Yorek M.A.; Alternatives to the streptozotocin-diabetic rodent. Int Rev Neurobiol 2016,127,89-112","journal-title":"Int Rev Neurobiol"},{"key":"ref=23","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1056\/NEJM198703053161007","volume":"316","author":"Greene D.A.","year":"1987","unstructured":"Greene D.A.; Lattimer S.A.; Sima A.A.; Sorbitol, phosphoinositides, and sodium-potassium-ATPase in the pathogenesis of diabetic complications. N Engl J Med 1987,316(10),599-606","journal-title":"N Engl J Med"},{"key":"ref=24","doi-asserted-by":"publisher","first-page":"1146","DOI":"10.1126\/science.182.4117.1146","volume":"182","author":"Dvornik E.","year":"1973","unstructured":"Dvornik E.; Simard-Duquesne N.; Krami M.; Sestanj K.; Gabbay K.H.; Kinoshita J.H.; Varma S.D.; Merola L.O.; Polyol accumulation in galactosemic and diabetic rats: control by an aldose reductase inhibitor. Science 1973,182(4117),1146-1148","journal-title":"Science"},{"key":"ref=25","doi-asserted-by":"publisher","first-page":"2756020","DOI":"10.1155\/2019\/2756020","volume":"2019","author":"Asano S.","year":"2019","unstructured":"Asano S.; Himeno T.; Hayami T.; Motegi M.; Inoue R.; Nakai-Shimoda H.; Miura-Yura E.; Morishita Y.; Kondo M.; Tsunekawa S.; Kato Y.; Kato K.; Naruse K.; Nakamura J.; Kamiya H.; Ranirestat improved nerve conduction velocities, sensory perception, and intraepidermal nerve fiber density in rats with overt diabetic polyneuropathy. J Diabetes Res 2019,2019,2756020","journal-title":"J Diabetes Res"},{"key":"ref=26","doi-asserted-by":"publisher","first-page":"345","DOI":"10.4103\/1673-5374.177745","volume":"11","author":"Li Q.R.","year":"2016","unstructured":"Li Q.R.; Wang Z.; Zhou W.; Fan S.R.; Ma R.; Xue L.; Yang L.; Li Y.S.; Tan H.L.; Shao Q.H.; Yang H.Y.; Epalrestat protects against diabetic peripheral neuropathy by alleviating oxidative stress and inhibiting polyol pathway. Neural Regen Res 2016,11(2),345-351","journal-title":"Neural Regen Res"},{"key":"ref=27","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1254\/jphs.08061FP","volume":"107","author":"Matsumoto T.","year":"2008","unstructured":"Matsumoto T.; Ono Y.; Kurono M.; Kuromiya A.; Nakamura K.; Bril V.; Ranirestat (AS-3201), a potent aldose reductase inhibitor, reduces sorbitol levels and improves motor nerve conduction velocity in streptozotocin-diabetic rats. J Pharmacol Sci 2008,107(3),231-237","journal-title":"J Pharmacol Sci"},{"key":"ref=28","doi-asserted-by":"publisher","first-page":"3085","DOI":"10.1007\/s00125-006-0400-7","volume":"49","author":"Kuzumoto Y.","year":"2006","unstructured":"Kuzumoto Y.; Kusunoki S.; Kato N.; Kihara M.; Low P.A.; Effect of the aldose reductase inhibitor fidarestat on experimental diabetic neuropathy in the rat. Diabetologia 2006,49(12),3085-3093","journal-title":"Diabetologia"},{"key":"ref=29","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1016\/S1056-8727(97)00093-7","volume":"12","author":"Raccah D.","year":"1998","unstructured":"Raccah D.; Coste T.; Cameron N.E.; Dufayet D.; Vague P.; Hohman T.C.; Effect of the aldose reductase inhibitor tolrestat on nerve conduction velocity, Na\/K ATPase activity, and polyols in red blood cells, sciatic nerve, kidney cortex, and kidney medulla of diabetic rats. J Diabetes Complications 1998,12(3),154-162","journal-title":"J Diabetes Complications"},{"key":"ref=30","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1007\/BF02427088","volume":"29","author":"Cameron N.E.","year":"1986","unstructured":"Cameron N.E.; Leonard M.B.; Ross I.S.; Whiting P.H.; The effects of sorbinil on peripheral nerve conduction velocity, polyol concentrations and morphology in the streptozotocin-diabetic rat. Diabetologia 1986,29(3),168-174","journal-title":"Diabetologia"},{"key":"ref=31","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1016\/0022-510X(83)90026-6","volume":"59","author":"Low P.A.","year":"1983","unstructured":"Low P.A.; Schmelzer J.D.; Peripheral nerve conduction studies in galactose-poisoned rats. Demonstration of increased resistance to ischemic conduction associated with endoneurial edema due to sugar alcohol accumulation. J Neurol Sci 1983,59(3),415-421","journal-title":"J Neurol Sci"},{"key":"ref=32","doi-asserted-by":"publisher","first-page":"794","DOI":"10.1136\/jnnp.39.8.794","volume":"39","author":"Sharma A.K.","year":"1976","unstructured":"Sharma A.K.; Thomas P.K.; Baker R.W.; Peripheral nerve abnormalities related to galactose administration in rats. J Neurol Neurosurg Psychiatry 1976,39(8),794-802","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"ref=33","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1016\/0168-8227(94)90037-X","volume":"25","author":"Kamijo M.","year":"1994","unstructured":"Kamijo M.; Basso M.; Cherian P.V.; Hohman T.C.; Sima A.A.; Galactosemia produces ARI-preventable nodal changes similar to those of diabetic neuropathy. Diabetes Res Clin Pract 1994,25(2),117-129","journal-title":"Diabetes Res Clin Pract"},{"key":"ref=34","doi-asserted-by":"publisher","first-page":"330","DOI":"10.1002\/dmrr.229","volume":"17","author":"Hansen S.H.","year":"2001","unstructured":"Hansen S.H.; The role of taurine in diabetes and the development of diabetic complications. Diabetes Metab Res Rev 2001,17(5),330-346","journal-title":"Diabetes Metab Res Rev"},{"key":"ref=35","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1016\/0014-2999(93)90277-O","volume":"237","author":"Carrington A.L.","year":"1993","unstructured":"Carrington A.L.; Calcutt N.A.; Ettlinger C.B.; Gustafsson T.; Tomlinson D.R.; Effects of treatment with myo-inositol or its 1,2,6-trisphosphate (PP56) on nerve conduction in streptozotocin-diabetes. Eur J Pharmacol 1993,237(2-3),257-263","journal-title":"Eur J Pharmacol"},{"key":"ref=36","doi-asserted-by":"publisher","first-page":"608","DOI":"10.1007\/BF00404069","volume":"36","author":"Stevens M","year":"1993","unstructured":"Stevens M; Lattimer S; Kamijo M; Van Huysen C; Sima A; Greene D; Osmotically-induced nerve taurine depletion and the compatible osmolyte hypothesis in experimental diabetic neuropathy in the rat. Diabetologia 1993,36,608-614","journal-title":"Diabetologia"},{"key":"ref=37","first-page":"574","volume":"40","author":"Schmidt R","year":"1991","unstructured":"Schmidt R; Plurad S; Coleman B; Williamsons ; Effects of sorbinil, dietary myo-inositol supplementation, and insulin on resolution of neuro axonal dystrophy in mesenteric nerves of streptozocin-induced diabetic rats. 1991,40,574-582"},{"key":"ref=38","doi-asserted-by":"publisher","first-page":"1030","DOI":"10.1016\/S0025-6196(12)61233-6","volume":"64","author":"Tomlinson D.R.","year":"1989","unstructured":"Tomlinson D.R.; Polyols and myo-inositol in diabetic neuropathy of mice and men. Mayo Clin Proc 1989,64(8),1030-1033","journal-title":"Mayo Clin Proc"},{"key":"ref=39","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1016\/S0026-0495(96)90059-1","volume":"45","author":"Yorek M.A.","year":"1996","unstructured":"Yorek M.A.; Wiese T.J.; Davidson E.P.; Dunlap J.A.; Conner C.E.; Reduced Na+\/K+ adenosine triphosphatase activity and motor nerve conduction velocity in L-fucose-fed rats is reversible after dietary normalization. Metabolism 1996,45(2),229-234","journal-title":"Metabolism"},{"key":"ref=40","doi-asserted-by":"publisher","first-page":"301","DOI":"10.2337\/diab.46.2.301","volume":"46","author":"Sima A.A.","year":"1997","unstructured":"Sima A.A.; Dunlap J.A.; Davidson E.P.; Wiese T.J.; Lightle R.L.; Greene D.A.; Yorek M.A.; Supplemental myo-inositol prevents L-fucose-induced diabetic neuropathy. Diabetes 1997,46(2),301-306","journal-title":"Diabetes"},{"key":"ref=41","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1016\/0026-0495(86)90192-7","volume":"35","author":"Pfeifer M.A.","year":"1986","unstructured":"Pfeifer M.A.; Clinical trials of sorbinil on nerve function. Metabolism 1986,35(4)(Suppl. 1),78-82","journal-title":"Metabolism"},{"key":"ref=42","doi-asserted-by":"publisher","first-page":"1458","DOI":"10.2337\/diacare.27.6.1458","volume":"27","author":"Boulton A.J.","year":"2004","unstructured":"Boulton A.J.; Malik R.A.; Arezzo J.C.; Sosenko J.M.; Diabetic somatic neuropathies. Diabetes Care 2004,27(6),1458-1486","journal-title":"Diabetes Care"},{"key":"ref=43","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1002\/dmrr.2397","volume":"29","author":"Boulton A.J.","year":"2013","unstructured":"Boulton A.J.; Kempler P.; Ametov A.; Ziegler D.; Whither pathogenetic treatments for diabetic polyneuropathy? Diabetes Metab Res Rev 2013,29(5),327-333","journal-title":"Diabetes Metab Res Rev"},{"key":"ref=44","doi-asserted-by":"publisher","first-page":"1538","DOI":"10.2337\/dc05-2370","volume":"29","author":"Hotta N.","year":"2006","unstructured":"Hotta N.; Akanuma Y.; Kawamori R.; Matsuoka K.; Oka Y.; Shichiri M.; Toyota T.; Nakashima M.; Yoshimura I.; Sakamoto N.; Shigeta Y.; Long-term clinical effects of epalrestat, an aldose reductase inhibitor, on diabetic peripheral neuropathy: the 3-year, multicenter, comparative Aldose Reductase Inhibitor-Diabetes Complications Trial. Diabetes Care 2006,29(7),1538-1544","journal-title":"Diabetes Care"},{"key":"ref=45","doi-asserted-by":"publisher","first-page":"S263","DOI":"10.1016\/j.diabres.2007.01.069","volume":"77","author":"Matsuoka K.","year":"2007","unstructured":"Matsuoka K.; Sakamoto N.; Akanuma Y.; Hotta N.; Shichiri M.; Toyota T.; Oka Y.; Kawamori R.; Shigeta Y.; A long-term effect of epalrestat on motor conduction velocity of diabetic patients: ARI-Diabetes Complications Trial (ADCT). Diabetes Res Clin Pract ADCT Study Group2007,77(Suppl. 1),S263-S268","journal-title":"Diabetes Res Clin Pract"},{"key":"ref=46","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1016\/j.jdiacomp.2008.10.005","volume":"24","author":"Kawai T.","year":"2010","unstructured":"Kawai T.; Takei I.; Tokui M.; Funae O.; Miyamoto K.; Tabata M.; Hirata T.; Saruta T.; Shimada A.; Itoh H.; Effects of epalrestat, an aldose reductase inhibitor, on diabetic peripheral neuropathy in patients with type 2 diabetes, in relation to suppression of N(\u025b)-carboxymethyl lysine. J Diabetes Complications 2010,24(6),424-432","journal-title":"J Diabetes Complications"},{"key":"ref=47","doi-asserted-by":"publisher","first-page":"68","DOI":"10.2337\/diacare.29.01.06.dc05-1447","volume":"29","author":"Bril V.","year":"2006","unstructured":"Bril V.; Buchanan R.A.; Long-term effects of ranirestat (AS-3201) on peripheral nerve function in patients with diabetic sensorimotor polyneuropathy. Diabetes Care 2006,29(1),68-72","journal-title":"Diabetes Care"},{"key":"ref=48","doi-asserted-by":"publisher","first-page":"1256","DOI":"10.2337\/dc08-2110","volume":"32","author":"Bril V.","year":"2009","unstructured":"Bril V.; Hirose T.; Tomioka S.; Buchanan R.; Ranirestat for the management of diabetic sensorimotor polyneuropathy. Diabetes Care Ranirestat Study Group2009,32(7),1256-1260","journal-title":"Diabetes Care"},{"key":"ref=49","doi-asserted-by":"publisher","first-page":"466","DOI":"10.1111\/jdi.12890","volume":"10","author":"Sekiguchi K.","year":"2019","unstructured":"Sekiguchi K.; Kohara N.; Baba M.; Komori T.; Naito Y.; Imai T.; Satoh J.; Yamaguchi Y.; Hamatani T.; Aldose reductase inhibitor ranirestat significantly improves nerve conduction velocity in diabetic polyneuropathy: A randomized double-blind placebo-controlled study in Japan. J Diabetes Investig Ranirestat Group2019,10(2),466-474","journal-title":"J Diabetes Investig"},{"key":"ref=50","doi-asserted-by":"publisher","first-page":"1315","DOI":"10.1056\/NEJM198805193182007","volume":"318","author":"Brownlee M.","year":"1988","unstructured":"Brownlee M.; Cerami A.; Vlassara H.; Advanced glycosylation end products in tissue and the biochemical basis of diabetic complications. N Engl J Med 1988,318(20),1315-1321","journal-title":"N Engl J Med"},{"key":"ref=51","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1016\/B978-0-444-53480-4.00028-X","volume":"126","author":"Zochodne D.W.","year":"2014","unstructured":"Zochodne D.W.; Mechanisms of diabetic neuron damage: Molecular pathways. Handb Clin Neurol 2014,126,379-399","journal-title":"Handb Clin Neurol"},{"key":"ref=52","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1152\/physrev.00045.2011","volume":"93","author":"Forbes J.M.","year":"2013","unstructured":"Forbes J.M.; Cooper M.E.; Mechanisms of diabetic complications. Physiol Rev 2013,93(1),137-188","journal-title":"Physiol Rev"},{"key":"ref=53","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1016\/j.trsl.2011.12.004","volume":"159","author":"Jack M.","year":"2012","unstructured":"Jack M.; Wright D.; Role of advanced glycation endproducts and glyoxalase I in diabetic peripheral sensory neuropathy. Transl Res 2012,159(5),355-365","journal-title":"Transl Res"},{"key":"ref=54","doi-asserted-by":"publisher","first-page":"330","DOI":"10.1055\/s-2001-17399","volume":"109","author":"Stracke H.","year":"2001","unstructured":"Stracke H.; Hammes H.P.; Werkmann D.; Mavrakis K.; Bitsch I.; Netzel M.; Geyer J.; K\u00f6pcke W.; Sauerland C.; Bretzel R.G.; Federlin K.F.; Efficacy of benfotiamine versus thiamine on function and glycation products of peripheral nerves in diabetic rats. Exp Clin Endocrinol Diabetes 2001,109(6),330-336","journal-title":"Exp Clin Endocrinol Diabetes"},{"key":"ref=55","doi-asserted-by":"publisher","first-page":"953","DOI":"10.2174\/138161208784139774","volume":"14","author":"Sugimoto K.","year":"2008","unstructured":"Sugimoto K.; Yasujima M.; Yagihashi S.; Role of advanced glycation end products in diabetic neuropathy. Curr Pharm Des 2008,14(10),953-961","journal-title":"Curr Pharm Des"},{"key":"ref=56","doi-asserted-by":"publisher","first-page":"784","DOI":"10.1196\/annals.1333.091","volume":"1043","author":"Cameron N.E.","year":"2005","unstructured":"Cameron N.E.; Gibson T.M.; Nangle M.R.; Cotter M.A.; Inhibitors of advanced glycation end product formation and neurovascular dysfunction in experimental diabetes. Ann N Y Acad Sci 2005,1043,784-792","journal-title":"Ann N Y Acad Sci"},{"key":"ref=57","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1055\/s-2004-814344","volume":"36","author":"Chen A.S.","year":"2004","unstructured":"Chen A.S.; Taguchi T.; Sugiura M.; Wakasugi Y.; Kamei A.; Wang M.W.; Miwa I.; Pyridoxal-aminoguanidine adduct is more effective than aminoguanidine in preventing neuropathy and cataract in diabetic rats. Horm Metab Res 2004,36(3),183-187","journal-title":"Horm Metab Res"},{"key":"ref=58","doi-asserted-by":"publisher","first-page":"47","DOI":"10.2337\/diab.41.1.47","volume":"41","author":"Yagihashi S.","year":"1992","unstructured":"Yagihashi S.; Kamijo M.; Baba M.; Yagihashi N.; Nagai K.; Effect of aminoguanidine on functional and structural abnormalities in peripheral nerve of STZ-induced diabetic rats. Diabetes 1992,41(1),47-52","journal-title":"Diabetes"},{"key":"ref=59","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1196\/annals.1433.059","volume":"1126","author":"Lukic I.K.","year":"2008","unstructured":"Lukic I.K.; Humpert P.M.; Nawroth P.P.; Bierhaus A.; The RAGE pathway: activation and perpetuation in the pathogenesis of diabetic neuropathy. Ann N Y Acad Sci 2008,1126,76-80","journal-title":"Ann N Y Acad Sci"},{"key":"ref=60","doi-asserted-by":"publisher","first-page":"766","DOI":"10.2174\/156652407783220705","volume":"7","author":"Toth C.","year":"2007","unstructured":"Toth C.; Martinez J.; Zochodne D.W.; RAGE, diabetes, and the nervous system. Curr Mol Med 2007,7(8),766-776","journal-title":"Curr Mol Med"},{"key":"ref=61","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1038\/nm834","volume":"9","author":"Hammes H.P.","year":"2003","unstructured":"Hammes H.P.; Du X.; Edelstein D.; Taguchi T.; Matsumura T.; Ju Q.; Lin J.; Bierhaus A.; Nawroth P.; Hannak D.; Neumaier M.; Bergfeld R.; Giardino I.; Brownlee M.; Benfotiamine blocks three major pathways of hyperglycemic damage and prevents experimental diabetic retinopathy. Nat Med 2003,9(3),294-299","journal-title":"Nat Med"},{"key":"ref=62","doi-asserted-by":"publisher","first-page":"600","DOI":"10.1055\/s-2008-1065351","volume":"116","author":"Stracke H.","year":"2008","unstructured":"Stracke H.; Gaus W.; Achenbach U.; Federlin K.; Bretzel R.G.; Benfotiamine in diabetic polyneuropathy (BENDIP): results of a randomised, double blind, placebo-controlled clinical study. Exp Clin Endocrinol Diabetes 2008,116(10),600-605","journal-title":"Exp Clin Endocrinol Diabetes"},{"key":"ref=63","doi-asserted-by":"publisher","first-page":"1598","DOI":"10.2337\/dc09-2241","volume":"33","author":"Alkhalaf A.","year":"2010","unstructured":"Alkhalaf A.; Klooster A.; van Oeveren W.; Achenbach U.; Kleefstra N.; Slingerland R.J.; Mijnhout G.S.; Bilo H.J.; Gans R.O.; Navis G.J.; Bakker S.J.; A double-blind, randomized, placebo-controlled clinical trial on benfotiamine treatment in patients with diabetic nephropathy. Diabetes Care 2010,33(7),1598-1601","journal-title":"Diabetes Care"},{"key":"ref=64","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1007\/s00125-008-1224-4","volume":"52","author":"Rabbani N.","year":"2009","unstructured":"Rabbani N.; Alam S.S.; Riaz S.; Larkin J.R.; Akhtar M.W.; Shafi T.; Thornalley P.J.; High-dose thiamine therapy for patients with type 2 diabetes and microalbuminuria: a randomised, double-blind placebo-controlled pilot study. Diabetologia 2009,52(2),208-212","journal-title":"Diabetologia"},{"key":"ref=65","doi-asserted-by":"publisher","first-page":"674987","DOI":"10.1155\/2014\/674987","volume":"2014","author":"Sandireddy R.","year":"2014","unstructured":"Sandireddy R.; Yerra V.G.; Areti A.; Komirishetty P.; Kumar A.; Neuroinflammation and oxidative stress in diabetic neuropathy: futuristic strategies based on these targets. Int J Endocrinol 2014,2014,674987","journal-title":"Int J Endocrinol"},{"key":"ref=66","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1080\/1071576031000083161","volume":"37","author":"Yorek M.A.","year":"2003","unstructured":"Yorek M.A.; The role of oxidative stress in diabetic vascular and neural disease. Free Radic Res 2003,37(5),471-480","journal-title":"Free Radic Res"},{"key":"ref=67","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1002\/dmrr.287","volume":"18","author":"van Dam P.S.","year":"2002","unstructured":"van Dam P.S.; Oxidative stress and diabetic neuropathy: pathophysiological mechanisms and treatment perspectives. Diabetes Metab Res Rev 2002,18(3),176-184","journal-title":"Diabetes Metab Res Rev"},{"key":"ref=68","doi-asserted-by":"publisher","first-page":"R335","DOI":"10.1152\/ajpregu.00605.2001","volume":"282","author":"Schnackenberg C.G.","year":"2002","unstructured":"Schnackenberg C.G.; Physiological and pathophysiological roles of oxygen radicals in the renal microvasculature. Am J Physiol Regul Integr Comp Physiol 2002,282(2),R335-R342","journal-title":"Am J Physiol Regul Integr Comp Physiol"},{"key":"ref=69","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1016\/S0891-5849(00)00373-7","volume":"30","author":"Radi R.","year":"2001","unstructured":"Radi R.; Peluffo G.; Alvarez M.N.; Naviliat M.; Cayota A.; Unraveling peroxynitrite formation in biological systems. Free Radic Biol Med 2001,30(5),463-488","journal-title":"Free Radic Biol Med"},{"key":"ref=70","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1046\/j.1463-1326.2002.00184.x","volume":"4","author":"Bayraktutan U.","year":"2002","unstructured":"Bayraktutan U.; Free radicals, diabetes and endothelial dysfunction. Diabetes Obes Metab 2002,4(4),224-238","journal-title":"Diabetes Obes Metab"},{"key":"ref=71","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1016\/S0899-9007(02)00758-X","volume":"18","author":"Fredstrom S.","year":"2002","unstructured":"Fredstrom S.; Nitric oxide, oxidative stress, and dietary antioxidants. Nutrition 2002,18(6),537-539","journal-title":"Nutrition"},{"key":"ref=72","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1002\/dmrr.196","volume":"17","author":"R\u00f6sen P.","year":"2001","unstructured":"R\u00f6sen P.; Nawroth P.P.; King G.; M\u00f6ller W.; Tritschler H.J.; Packer L.; The role of oxidative stress in the onset and progression of diabetes and its complications: a summary of a Congress Series sponsored by UNESCO-MCBN, the American Diabetes Association and the German Diabetes Society. Diabetes Metab Res Rev 2001,17(3),189-212","journal-title":"Diabetes Metab Res Rev"},{"key":"ref=73","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/S0014-5793(97)01159-9","volume":"416","author":"Korshunov S.S.","year":"1997","unstructured":"Korshunov S.S.; Skulachev V.P.; Starkov A.A.; High protonic potential actuates a mechanism of production of reactive oxygen species in mitochondria. FEBS Lett 1997,416(1),15-18","journal-title":"FEBS Lett"},{"key":"ref=74","doi-asserted-by":"publisher","first-page":"1341","DOI":"10.1172\/JCI11235","volume":"108","author":"Du X.L.","year":"2001","unstructured":"Du X.L.; Edelstein D.; Dimmeler S.; Ju Q.; Sui C.; Brownlee M.; Hyperglycemia inhibits endothelial nitric oxide synthase activity by posttranslational modification at the Akt site. J Clin Invest 2001,108(9),1341-1348","journal-title":"J Clin Invest"},{"key":"ref=75","doi-asserted-by":"publisher","first-page":"813","DOI":"10.1038\/414813a","volume":"414","author":"Brownlee M.","year":"2001","unstructured":"Brownlee M.; Biochemistry and molecular cell biology of diabetic complications. Nature 2001,414(6865),813-820","journal-title":"Nature"},{"key":"ref=76","doi-asserted-by":"publisher","first-page":"787","DOI":"10.1038\/35008121","volume":"404","author":"Nishikawa T.","year":"2000","unstructured":"Nishikawa T.; Edelstein D.; Du X.L.; Yamagishi S.; Matsumura T.; Kaneda Y.; Yorek M.A.; Beebe D.; Oates P.J.; Hammes H.P.; Giardino I.; Brownlee M.; Normalizing mitochondrial superoxide production blocks three pathways of hyperglycaemic damage. Nature 2000,404(6779),787-790","journal-title":"Nature"},{"key":"ref=77","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1080\/1071576021000028442","volume":"37","author":"Coppey L.J.","year":"2003","unstructured":"Coppey L.J.; Gellett J.S.; Davidson E.P.; Yorek M.A.; Preventing superoxide formation in epineurial arterioles of the sciatic nerve from diabetic rats restores endothelium-dependent vasodilation. Free Radic Res 2003,37(1),33-40","journal-title":"Free Radic Res"},{"key":"ref=78","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1155\/EDR.2000.131","volume":"1","author":"Coppey L.J.","year":"2000","unstructured":"Coppey L.J.; Davidson E.P.; Dunlap J.A.; Lund D.D.; Yorek M.A.; Slowing of motor nerve conduction velocity in streptozotocin-induced diabetic rats is preceded by impaired vasodilation in arterioles that overlie the sciatic nerve. Int J Exp Diabetes Res 2000,1(2),131-143","journal-title":"Int J Exp Diabetes Res"},{"key":"ref=79","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1053\/meta.2002.29958","volume":"51","author":"Yorek M.A.","year":"2002","unstructured":"Yorek M.A.; Dunlap J.A.; Effect of increased concentration of D-glucose or L-fucose on monocyte adhesion to endothelial cell monolayers and activation of nuclear factor-kappaB. Metabolism 2002,51(2),225-234","journal-title":"Metabolism"},{"key":"ref=80","doi-asserted-by":"publisher","first-page":"1905","DOI":"10.1172\/JCI656","volume":"101","author":"Morigi M.","year":"1998","unstructured":"Morigi M.; Angioletti S.; Imberti B.; Donadelli R.; Micheletti G.; Figliuzzi M.; Remuzzi A.; Zoja C.; Remuzzi G.; Leukocyte-endothelial interaction is augmented by high glucose concentrations and hyperglycemia in a NF-kB-dependent fashion. J Clin Invest 1998,101(9),1905-1915","journal-title":"J Clin Invest"},{"key":"ref=81","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1097\/00005344-199710000-00019","volume":"30","author":"Pieper G","year":"1997","unstructured":"Pieper G; Riaz-ul-Haq. ; Activation of nuclear factor -\u03baB in cultured endothelial cells by increased glucose concentration: prevention by calphostin C. J Card Pharm 1997,30,528-532","journal-title":"J Card Pharm"},{"key":"ref=82","doi-asserted-by":"publisher","first-page":"752","DOI":"10.1016\/S0891-5849(99)00079-9","volume":"27","author":"Du X.","year":"1999","unstructured":"Du X.; Stocklauser-F\u00e4rber K.; R\u00f6sen P.; Generation of reactive oxygen intermediates, activation of NF-kappaB, and induction of apoptosis in human endothelial cells by glucose: role of nitric oxide synthase? Free Radic Biol Med 1999,27(7-8),752-763","journal-title":"Free Radic Biol Med"},{"key":"ref=83","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1016\/S0008-6363(99)00425-3","volume":"46","author":"Hattori Y.","year":"2000","unstructured":"Hattori Y.; Hattori S.; Sato N.; Kasai K.; High-glucose-induced nuclear factor kappaB activation in vascular smooth muscle cells. Cardiovasc Res 2000,46(1),188-197","journal-title":"Cardiovasc Res"},{"key":"ref=84","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1016\/S0021-9150(97)00286-4","volume":"138","author":"Takami S.","year":"1998","unstructured":"Takami S.; Yamashita S.; Kihara S.; Kameda-Takemura K.; Matsuzawa Y.; High concentration of glucose induces the expression of intercellular adhesion molecule-1 in human umbilical vein endothelial cells. Atherosclerosis 1998,138(1),35-41","journal-title":"Atherosclerosis"},{"key":"ref=85","doi-asserted-by":"publisher","first-page":"1103","DOI":"10.2337\/diab.43.9.1103","volume":"43","author":"Kim J.A.","year":"1994","unstructured":"Kim J.A.; Berliner J.A.; Natarajan R.D.; Nadler J.L.; Evidence that glucose increases monocyte binding to human aortic endothelial cells. Diabetes 1994,43(9),1103-1107","journal-title":"Diabetes"},{"key":"ref=86","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1080\/15438600490277824","volume":"5","author":"Yorek M.A.","year":"2004","unstructured":"Yorek M.A.; Coppey L.J.; Gellett J.S.; Davidson E.P.; Lund D.D.; Effect of fidarestat and alpha-lipoic acid on diabetes-induced epineurial arteriole vascular dysfunction. Exp Diabesity Res 2004,5(2),123-135","journal-title":"Exp Diabesity Res"},{"key":"ref=87","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1111\/j.1463-1326.2007.00814.x","volume":"10","author":"Oltman C.L.","year":"2008","unstructured":"Oltman C.L.; Davidson E.P.; Coppey L.J.; Kleinschmidt T.L.; Lund D.D.; Adebara E.T.; Yorek M.A.; Vascular and neural dysfunction in Zucker diabetic fatty rats: a difficult condition to reverse. Diabetes Obes Metab 2008,10(1),64-74","journal-title":"Diabetes Obes Metab"},{"key":"ref=88","doi-asserted-by":"publisher","first-page":"S31","DOI":"10.2337\/diab.46.2.S31","volume":"46","author":"Cameron N.E.","year":"1997","unstructured":"Cameron N.E.; Cotter M.A.; Metabolic and vascular factors in the pathogenesis of diabetic neuropathy. Diabetes 1997,46(Suppl. 2),S31-S37","journal-title":"Diabetes"},{"key":"ref=89","doi-asserted-by":"publisher","first-page":"1927","DOI":"10.2337\/diabetes.50.8.1927","volume":"50","author":"Coppey L.J.","year":"2001","unstructured":"Coppey L.J.; Gellett J.S.; Davidson E.P.; Dunlap J.A.; Lund D.D.; Yorek M.A.; Effect of antioxidant treatment of streptozotocin-induced diabetic rats on endoneurial blood flow, motor nerve conduction velocity, and vascular reactivity of epineurial arterioles of the sciatic nerve. Diabetes 2001,50(8),1927-1937","journal-title":"Diabetes"},{"key":"ref=90","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1080\/15604280212525","volume":"3","author":"Coppey L.J.","year":"2002","unstructured":"Coppey L.J.; Gellett J.S.; Davidson E.P.; Dunlap J.A.; Yorek M.A.; Effect of treating streptozotocin-induced diabetic rats with sorbinil, myo-inositol or aminoguanidine on endoneurial blood flow, motor nerve conduction velocity and vascular function of epineurial arterioles of the sciatic nerve. Int J Exp Diabetes Res 2002,3(1),21-36","journal-title":"Int J Exp Diabetes Res"},{"key":"ref=91","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1038\/sj.bjp.0704216","volume":"134","author":"Coppey L.J.","year":"2001","unstructured":"Coppey L.J.; Gellett J.S.; Davidson E.P.; Dunlap J.A.; Lund D.D.; Salvemini D.; Yorek M.A.; Effect of M40403 treatment of diabetic rats on endoneurial blood flow, motor nerve conduction velocity and vascular function of epineurial arterioles of the sciatic nerve. Br J Pharmacol 2001,134(1),21-29","journal-title":"Br J Pharmacol"},{"key":"ref=92","doi-asserted-by":"publisher","first-page":"E1067","DOI":"10.1152\/ajpendo.00173.2002","volume":"283","author":"Yorek M.A.","year":"2002","unstructured":"Yorek M.A.; Coppey L.J.; Gellett J.S.; Davidson E.P.; Bing X.; Lund D.D.; Dillon J.S.; Effect of treatment of diabetic rats with dehydroepiandrosterone on vascular and neural function. Am J Physiol Endocrinol Metab 2002,283(5),E1067-E1075","journal-title":"Am J Physiol Endocrinol Metab"},{"key":"ref=93","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1007\/BF00400231","volume":"36","author":"Cameron N.E.","year":"1993","unstructured":"Cameron N.E.; Cotter M.A.; Maxfield E.K.; Anti-oxidant treatment prevents the development of peripheral nerve dysfunction in streptozotocin-diabetic rats. Diabetologia 1993,36(4),299-304","journal-title":"Diabetologia"},{"key":"ref=94","doi-asserted-by":"publisher","first-page":"1159","DOI":"10.1172\/JCI118104","volume":"96","author":"Cameron N.E.","year":"1995","unstructured":"Cameron N.E.; Cotter M.A.; Neurovascular dysfunction in diabetic rats. Potential contribution of autoxidation and free radicals examined using transition metal chelating agents. J Clin Invest 1995,96(2),1159-1163","journal-title":"J Clin Invest"},{"key":"ref=95","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1016\/S0168-8227(99)00043-1","volume":"45","author":"Cameron N.E.","year":"1999","unstructured":"Cameron N.E.; Cotter M.A.; Effects of antioxidants on nerve and vascular dysfunction in experimental diabetes. Diabetes Res Clin Pract 1999,45(2-3),137-146","journal-title":"Diabetes Res Clin Pract"},{"key":"ref=96","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1007\/s001250051161","volume":"42","author":"Keegan A.","year":"1999","unstructured":"Keegan A.; Cotter M.A.; Cameron N.E.; Effects of diabetes and treatment with the antioxidant \u03b1-lipoic acid on endothelial and neurogenic responses of corpus cavernosum in rats. Diabetologia 1999,42(3),343-350","journal-title":"Diabetologia"},{"key":"ref=97","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1007\/BF00400086","volume":"38","author":"Karasu C.","year":"1995","unstructured":"Karasu C.; Dewhurst M.; Stevens E.J.; Tomlinson D.R.; Effects of anti-oxidant treatment on sciatic nerve dysfunction in streptozotocin- diabetic rats; comparison with essential fatty acids. Diabetologia 1995,38(2),129-134","journal-title":"Diabetologia"},{"key":"ref=98","doi-asserted-by":"publisher","first-page":"734","DOI":"10.1097\/00005344-199712000-00006","volume":"30","author":"Pieper G.M.","year":"1997","unstructured":"Pieper G.M.; Siebeneich W.; Diabetes-induced endothelial dysfunction is prevented by long-term treatment with the modified iron chelator, hydroxyethyl starch conjugated-deferoxamine. J Cardiovasc Pharmacol 1997,30(6),734-738","journal-title":"J Cardiovasc Pharmacol"},{"key":"ref=99","doi-asserted-by":"publisher","first-page":"963","DOI":"10.1038\/sj.bjp.0703393","volume":"130","author":"De Vriese A.S.","year":"2000","unstructured":"De Vriese A.S.; Verbeuren T.J.; Van de Voorde J.; Lameire N.H.; Vanhoutte P.M.; Endothelial dysfunction in diabetes. Br J Pharmacol 2000,130(5),963-974","journal-title":"Br J Pharmacol"},{"key":"ref=100","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1016\/S0891-5849(01)00564-0","volume":"31","author":"Cameron N.E.","year":"2001","unstructured":"Cameron N.E.; Jack A.M.; Cotter M.A.; Effect of alpha-lipoic acid on vascular responses and nociception in diabetic rats. Free Radic Biol Med 2001,31(1),125-135","journal-title":"Free Radic Biol Med"},{"key":"ref=101","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1007\/s001250051669","volume":"44","author":"Cameron N.E.","year":"2001","unstructured":"Cameron N.E.; Cotter M.A.; Effects of an extracellular metal chelator on neurovascular function in diabetic rats. Diabetologia 2001,44(5),621-628","journal-title":"Diabetologia"},{"key":"ref=102","doi-asserted-by":"publisher","first-page":"1091","DOI":"10.1080\/1071576021000028325","volume":"36","author":"Inkster M.E.","year":"2002","unstructured":"Inkster M.E.; Cotter M.A.; Cameron N.E.; Effects of trientine, a metal chelator, on defective endothelium-dependent relaxation in the mesenteric vasculature of diabetic rats. Free Radic Res 2002,36(10),1091-1099","journal-title":"Free Radic Res"},{"key":"ref=103","doi-asserted-by":"crossref","first-page":"31656","DOI":"10.1038\/srep31656","volume":"6","author":"Ma J.","year":"2016","unstructured":"Ma J.; Shi M.; Zhang X.; GLP-1R agonists ameliorate peripheral nerve dysfunction and inflammation via p38 MAPK\/NF-\u03baB signaling pathways in streptozotocin-induced diabetic rats. Sci Rep 2016,6,31656","journal-title":"Sci Rep"},{"key":"ref=104","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1007\/s12035-013-8537-0","volume":"49","author":"Chen L.","year":"2014","unstructured":"Chen L.; Li B.; Chen B.; Thymoquinone alleviates the experimental diabetic peripheral neuropathy by modulation of inflammation. Mol Neurobiol 2014,49,536-546","journal-title":"Mol Neurobiol"},{"key":"ref=105","doi-asserted-by":"publisher","DOI":"10.1007\/978-981-32-9636-7_22","volume":"Vol. 1190","author":"Naruse K.","year":"2019","unstructured":"Naruse K.; Myelin Advances in Experimental Medicine and Biology 2019,Vol. 1190","journal-title":"Myelin Advances in Experimental Medicine and Biology"},{"key":"ref=106","doi-asserted-by":"publisher","first-page":"1709","DOI":"10.1142\/S0192415X17500926","volume":"45","author":"Zan Y.","year":"2017","unstructured":"Zan Y.; Kuai C.X.; Qiu Z.X.; Huang F.; Kuai C, Qiu Z, Huang F. Berberine ameliorates diabetic neuropathy: TRPV modulation by PKC pathway. Am J Chin Med 2017,45(8),1709-1723","journal-title":"Am J Chin Med"},{"key":"ref=107","doi-asserted-by":"publisher","first-page":"557","DOI":"10.5966\/sctm.2012-0025","volume":"1","author":"Waterman R.S.","year":"2012","unstructured":"Waterman R.S.; Morgenweck J.; Nossaman B.D.; Scandurro A.E.; Scandurro S.A.; Betancourt A.M.; Anti-inflammatory mesenchymal stem cells (MSC2) attenuate symptoms of painful diabetic peripheral neuropathy. Stem Cells Transl Med 2012,1(7),557-565","journal-title":"Stem Cells Transl Med"},{"key":"ref=108","doi-asserted-by":"publisher","first-page":"456","DOI":"10.1016\/j.neuropharm.2009.06.013","volume":"57","author":"Kuhad A.","year":"2009","unstructured":"Kuhad A.; Chopra K.; Tocotrienol attenuates oxidative-nitrosative stress and inflammatory cascade in experimental model of diabetic neuropathy. Neuropharmacology 2009,57(4),456-462","journal-title":"Neuropharmacology"},{"key":"ref=109","doi-asserted-by":"publisher","first-page":"1147","DOI":"10.1016\/j.jnutbio.2015.05.005","volume":"26","author":"Li M.Y.","year":"2015","unstructured":"Li M.Y.; Wang Y.Y.; Cao R.; Hou X.H.; Zhang L.; Yang R.H.; Wang F.; Dietary fish oil inhibits mechanical allodynia and thermal hyperalgesia in diabetic rats by blocking nuclear factor-\u03baB-mediated inflammatory pathways. J Nutr Biochem 2015,26(11),1147-1155","journal-title":"J Nutr Biochem"},{"key":"ref=110","doi-asserted-by":"publisher","first-page":"3435","DOI":"10.2337\/diabetes.54.12.3435","volume":"54","author":"Obrosova I.G.","year":"2005","unstructured":"Obrosova I.G.; Drel V.R.; Pacher P.; Ilnytska O.; Wang Z.Q.; Stevens M.J.; Yorek M.A.; Oxidative-nitrosative stress and poly(ADP-ribose) polymerase (PARP) activation in experimental diabetic neuropathy: the relation is revisited. Diabetes 2005,54(12),3435-3441","journal-title":"Diabetes"},{"key":"ref=111","doi-asserted-by":"publisher","first-page":"E1645","DOI":"10.1152\/ajpendo.00479.2007","volume":"293","author":"Obrosova I.G.","year":"2007","unstructured":"Obrosova I.G.; Drel V.R.; Oltman C.L.; Mashtalir N.; Tibrewala J.; Groves J.T.; Yorek M.A.; Role of nitrosative stress in early neuropathy and vascular dysfunction in streptozotocin-diabetic rats. Am J Physiol Endocrinol Metab 2007,293(6),E1645-E1655","journal-title":"Am J Physiol Endocrinol Metab"},{"key":"ref=112","doi-asserted-by":"publisher","first-page":"1686","DOI":"10.2337\/db06-0067","volume":"55","author":"Ilnytska O.","year":"2006","unstructured":"Ilnytska O.; Lyzogubov V.V.; Stevens M.J.; Drel V.R.; Mashtalir N.; Pacher P.; Yorek M.A.; Obrosova I.G.; Poly(ADP-ribose) polymerase inhibition alleviates experimental diabetic sensory neuropathy. Diabetes 2006,55(6),1686-1694","journal-title":"Diabetes"},{"key":"ref=113","doi-asserted-by":"publisher","first-page":"669","DOI":"10.1002\/dmrr.2549","volume":"30","author":"Stavniichuk R.","year":"2014","unstructured":"Stavniichuk R.; Shevalye H.; Lupachyk S.; Obrosov A.; Groves J.T.; Obrosova I.G.; Yorek M.A.; Peroxynitrite and protein nitration in the pathogenesis of diabetic peripheral neuropathy. Diabetes Metab Res Rev 2014,30(8),669-678","journal-title":"Diabetes Metab Res Rev"},{"key":"ref=114","doi-asserted-by":"publisher","first-page":"112967","DOI":"10.1016\/j.expneurol.2019.112967","volume":"320","author":"Elzinga S.","year":"2019","unstructured":"Elzinga S.; Murdock B.J.; Guo K.; Hayes J.M.; Tabbey M.A.; Hur J.; Feldman E.L.; Toll-like receptors and inflammation in metabolic neuropathy; a role in early versus late disease? Exp Neurol 2019,320,112967","journal-title":"Exp Neurol"},{"key":"ref=115","doi-asserted-by":"publisher","first-page":"2178","DOI":"10.2337\/diacare.27.9.2178","volume":"27","author":"Ziegler D.","year":"2004","unstructured":"Ziegler D.; Sohr C.G.H.; Nourooz-Zadeh J.; Oxidative stress and antioxidant defense in relation to the severity of diabetic polyneuropathy and cardiovascular autonomic neuropathy. Diabetes Care 2004,27(9),2178-2183","journal-title":"Diabetes Care"},{"key":"ref=116","doi-asserted-by":"publisher","first-page":"680","DOI":"10.2337\/dc08-2011","volume":"32","author":"Herder C.","year":"2009","unstructured":"Herder C.; Lankisch M.; Ziegler D.; Rathmann W.; Koenig W.; Illig T.; D\u00f6ring A.; Thorand B.; Holle R.; Giani G.; Martin S.; Meisinger C.; Subclinical inflammation and diabetic polyneuropathy: MONICA\/KORA Survey F3 (Augsburg, Germany). Diabetes Care 2009,32(4),680-682","journal-title":"Diabetes Care"},{"key":"ref=117","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1530\/EJE-15-1010","volume":"174","author":"Schamarek I.","year":"2016","unstructured":"Schamarek I.; Herder C.; Nowotny B.; Carstensen-Kirberg M.; Stra\u00dfburger K.; Nowotny P.; Strom A.; P\u00fcttgen S.; M\u00fcssig K.; Szendroedi J.; Roden M.; Ziegler D.; Adiponectin, markers of subclinical inflammation and nerve conduction in individuals with recently diagnosed type 1 and type 2 diabetes. Eur J Endocrinol German Diabetes Study Group2016,174(4),433-443","journal-title":"Eur J Endocrinol"},{"key":"ref=118","doi-asserted-by":"publisher","first-page":"569","DOI":"10.2337\/dc16-2259","volume":"40","author":"Herder C.","year":"2017","unstructured":"Herder C.; Kannenberg J.M.; Huth C.; Carstensen-Kirberg M.; Rathmann W.; Koenig W.; Heier M.; P\u00fcttgen S.; Thorand B.; Peters A.; Roden M.; Meisinger C.; Ziegler D.; Proinflammatory cytokines predict the incidence and progression of distal sensorimotor polyneuropathy: KORA F\/FF study. Diabetes Care 2017,40(4),569-576","journal-title":"Diabetes Care"},{"key":"ref=119","doi-asserted-by":"publisher","first-page":"666","DOI":"10.1097\/WCO.0000000000000723","volume":"32","author":"Zochodne D.W.","year":"2019","unstructured":"Zochodne D.W.; The challenges of diabetic polyneuropathy: a brief update. Curr Opin Neurol 2019,32(5),666-675","journal-title":"Curr Opin Neurol"},{"key":"ref=120","doi-asserted-by":"publisher","first-page":"2054","DOI":"10.2337\/dc11-0503","volume":"34","author":"Ziegler D.","year":"2011","unstructured":"Ziegler D.; Low P.A.; Litchy W.J.; Boulton A.J.; Vinik A.I.; Freeman R.; Samigullin R.; Tritschler H.; Munzel U.; Maus J.; Sch\u00fctte K.; Dyck P.J.; Efficacy and safety of antioxidant treatment with \u03b1-lipoic acid over 4 years in diabetic polyneuropathy: the NATHAN 1 trial. Diabetes Care 2011,34(9),2054-2060","journal-title":"Diabetes Care"},{"key":"ref=121","doi-asserted-by":"publisher","first-page":"2721","DOI":"10.1517\/14656566.2014.972935","volume":"15","author":"Papanas N.","year":"2014","unstructured":"Papanas N.; Ziegler D.; Efficacy of \u03b1-lipoic acid in diabetic neuropathy. Expert Opin Pharmacother 2014,15(18),2721-2731","journal-title":"Expert Opin Pharmacother"},{"key":"ref=122","doi-asserted-by":"publisher","first-page":"770","DOI":"10.2337\/diacare.26.3.770","volume":"26","author":"Ametov A.S.","year":"2003","unstructured":"Ametov A.S.; Barinov A.; Dyck P.J.; Hermann R.; Kozlova N.; Litchy W.J.; Low P.A.; Nehrdich D.; Novosadova M.; O\u2019Brien P.C.; Reljanovic M.; Samigullin R.; Schuette K.; Strokov I.; Tritschler H.J.; Wessel K.; Yakhno N.; Ziegler D.; The sensory symptoms of diabetic polyneuropathy are improved with alpha-lipoic acid: the SYDNEY trial. Diabetes Care SYDNEY Trial Study Group2003,26(3),770-776","journal-title":"Diabetes Care"},{"key":"ref=123","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1111\/j.1464-5491.2004.01109.x","volume":"21","author":"Ziegler D.","year":"2004","unstructured":"Ziegler D.; Nowak H.; Kempler P.; Vargha P.; Low P.A.; Treatment of symptomatic diabetic polyneuropathy with the antioxidant alpha-lipoic acid: a meta-analysis. Diabet Med 2004,21(2),114-121","journal-title":"Diabet Med"},{"key":"ref=124","doi-asserted-by":"publisher","first-page":"2365","DOI":"10.2337\/dc06-1216","volume":"29","author":"Ziegler D.","year":"2006","unstructured":"Ziegler D.; Ametov A.; Barinov A.; Dyck P.J.; Gurieva I.; Low P.A.; Munzel U.; Yakhno N.; Raz I.; Novosadova M.; Maus J.; Samigullin R.; Oral treatment with alpha-lipoic acid improves symptomatic diabetic polyneuropathy: the SYDNEY 2 trial. Diabetes Care 2006,29(11),2365-2370","journal-title":"Diabetes Care"},{"key":"ref=125","doi-asserted-by":"publisher","first-page":"1021","DOI":"10.1139\/cjpp-2014-0353","volume":"93","author":"Rochette L.","year":"2015","unstructured":"Rochette L.; Ghibu S.; Muresan A.; Vergely C.; Alpha-lipoic acid: molecular mechanisms and therapeutic potential in diabetes. Can J Physiol Pharmacol 2015,93(12),1021-1027","journal-title":"Can J Physiol Pharmacol"},{"key":"ref=126","doi-asserted-by":"publisher","first-page":"1087","DOI":"10.4103\/1673-5374.233453","volume":"13","author":"Zhao M.","year":"2018","unstructured":"Zhao M.; Chen J.Y.; Chu Y.D.; Zhu Y.B.; Luo L.; Bu S.Z.; Efficacy of epalrestat plus \u03b1-lipoic acid combination therapy versus monotherapy in patients with diabetic peripheral neuropathy: a meta-analysis of 20 randomized controlled trials. Neural Regen Res 2018,13(6),1087-1095","journal-title":"Neural Regen Res"},{"key":"ref=127","doi-asserted-by":"publisher","first-page":"1824","DOI":"10.2337\/diabetes.53.7.1824","volume":"53","author":"Brussee V.","year":"2004","unstructured":"Brussee V.; Cunningham F.A.; Zochodne D.W.; Direct insulin signaling of neurons reverses diabetic neuropathy. Diabetes 2004,53(7),1824-1830","journal-title":"Diabetes"},{"key":"ref=128","doi-asserted-by":"publisher","first-page":"E407","DOI":"10.1152\/ajpendo.00444.2016","volume":"312","author":"de la Hoz C.L.","year":"2017","unstructured":"de la Hoz C.L.; Cheng C.; Fernyhough P.; Zochodne D.W.; A model of chronic diabetic polyneuropathy: benefits from intranasal insulin are modified by sex and RAGE deletion. Am J Physiol Endocrinol Metab 2017,312(5),E407-E419","journal-title":"Am J Physiol Endocrinol Metab"},{"key":"ref=129","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1016\/B978-0-444-53480-4.00027-8","volume":"126","author":"Fernyhough P.","year":"2014","unstructured":"Fernyhough P.; McGavock J.; Mechanisms of disease: Mitochondrial dysfunction in sensory neuropathy and other complications in diabetes. Handb Clin Neurol 2014,126,353-377","journal-title":"Handb Clin Neurol"},{"key":"ref=130","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1007\/s11892-015-0671-9","volume":"15","author":"Fernyhough P.","year":"2015","unstructured":"Fernyhough P.; Mitochondrial dysfunction in diabetic neuropathy: a series of unfortunate metabolic events. Curr Diab Rep 2015,15(11),89","journal-title":"Curr Diab Rep"},{"key":"ref=131","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1155\/EDR.2003.271","volume":"4","author":"Pittenger G.","year":"2003","unstructured":"Pittenger G.; Vinik A.; Nerve growth factor and diabetic neuropathy. Exp Diabesity Res 2003,4(4),271-285","journal-title":"Exp Diabesity Res"},{"key":"ref=132","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1098\/rstb.1996.0042","volume":"351","author":"Tomlinson D.R.","year":"1996","unstructured":"Tomlinson D.R.; Fernyhough P.; Diemel L.T.; Neurotrophins and peripheral neuropathy. Philos Trans R Soc Lond B Biol Sci 1996,351(1338),455-462","journal-title":"Philos Trans R Soc Lond B Biol Sci"},{"key":"ref=133","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1080\/15438600490486732","volume":"5","author":"Yorek M.A.","year":"2004","unstructured":"Yorek M.A.; Coppey L.J.; Gellett J.S.; Davidson E.P.; Sensory nerve innervation of epineurial arterioles of the sciatic nerve containing calcitonin gene-related peptide: effect of streptozotocin-induced diabetes. Exp Diabesity Res 2004,5(3),187-193","journal-title":"Exp Diabesity Res"},{"key":"ref=134","doi-asserted-by":"publisher","first-page":"181","DOI":"10.2337\/db07-0895","volume":"57","author":"Karamoysoyli E.","year":"2008","unstructured":"Karamoysoyli E.; Burnand R.C.; Tomlinson D.R.; Gardiner N.J.; Neuritin mediates nerve growth factor-induced axonal regeneration and is deficient in experimental diabetic neuropathy. Diabetes 2008,57(1),181-189","journal-title":"Diabetes"},{"key":"ref=135","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1016\/j.expneurol.2005.03.001","volume":"194","author":"Huang T-J.","year":"2005","unstructured":"Huang T-J.; Sayers N.M.; Verkhratsky A.; Fernyhough P.; Neurotrophin-3 prevents mitochondrial dysfunction in sensory neurons of streptozotocin-diabetic rats. Exp Neurol 2005,194(1),279-283","journal-title":"Exp Neurol"},{"key":"ref=136","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1016\/j.nbd.2011.08.011","volume":"45","author":"Cheng H.T.","year":"2012","unstructured":"Cheng H.T.; Dauch J.R.; Hayes J.M.; Yanik B.M.; Feldman E.L.; Nerve growth factor\/p38 signaling increases intraepidermal nerve fiber densities in painful neuropathy of type 2 diabetes. Neurobiol Dis 2012,45(1),280-287","journal-title":"Neurobiol Dis"},{"key":"ref=137","doi-asserted-by":"publisher","first-page":"47","DOI":"10.2174\/138945008783431727","volume":"9","author":"Calcutt N.A.","year":"2008","unstructured":"Calcutt N.A.; Jolivalt C.G.; Fernyhough P.; Growth factors as therapeutics for diabetic neuropathy. Curr Drug Targets 2008,9(1),47-59","journal-title":"Curr Drug Targets"},{"key":"ref=138","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1055\/s-2008-1040971","volume":"16","author":"Zochodne D.W.","year":"1996","unstructured":"Zochodne D.W.; Neurotrophins and other growth factors in diabetic neuropathy. Semin Neurol 1996,16(2),153-161","journal-title":"Semin Neurol"},{"key":"ref=139","doi-asserted-by":"publisher","first-page":"436","DOI":"10.1016\/j.jdiacomp.2013.04.003","volume":"27","author":"Smith A.G.","year":"2013","unstructured":"Smith A.G.; Singleton J.R.; Obesity and hyperlipidemia are risk factors for early diabetic neuropathy. J Diabetes Complications 2013,27(5),436-442","journal-title":"J Diabetes Complications"},{"key":"ref=140","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1111\/j.1085-9489.2005.00047.x","volume":"10","author":"Miscio G.","year":"2005","unstructured":"Miscio G.; Guastamacchia G.; Brunani A.; Priano L.; Baudo S.; Mauro A.; Obesity and peripheral neuropathy risk: a dangerous liaison. J Peripher Nerv Syst 2005,10(4),354-358","journal-title":"J Peripher Nerv Syst"},{"key":"ref=141","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1002\/ana.23986","volume":"74","author":"Callaghan B.","year":"2013","unstructured":"Callaghan B.; Feldman E.; The metabolic syndrome and neuropathy: therapeutic challenges and opportunities. Ann Neurol 2013,74(3),397-403","journal-title":"Ann Neurol"},{"key":"ref=142","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1002\/dmrr.1088","volume":"26","author":"Davidson E.P.","year":"2010","unstructured":"Davidson E.P.; Coppey L.J.; Calcutt N.A.; Oltman C.L.; Yorek M.A.; Diet-induced obesity in Sprague-Dawley rats causes microvascular and neural dysfunction. Diabetes Metab Res Rev 2010,26(4),306-318","journal-title":"Diabetes Metab Res Rev"},{"key":"ref=143","doi-asserted-by":"publisher","first-page":"1367","DOI":"10.2147\/DMSO.S247571","volume":"13","author":"Coppey L.","year":"2020","unstructured":"Coppey L.; Davidson E.; Shevalye H.; Obrosov A.; Torres M.; Yorek M.A.; Progressive loss of corneal nerve fibers and sensitivity in rats modeling obesity and type 2 diabetes is reversible with omega-3 fatty acid intervention: supporting cornea analysis as a marker for peripheral neuropathy and treatment. Diabetes Metab Syndr Obes 2020,13,1367-1384","journal-title":"Diabetes Metab Syndr Obes"},{"key":"ref=144","doi-asserted-by":"publisher","first-page":"E113","DOI":"10.1152\/ajpendo.00594.2004","volume":"289","author":"Oltman C.L.","year":"2005","unstructured":"Oltman C.L.; Coppey L.J.; Gellett J.S.; Davidson E.P.; Lund D.D.; Yorek M.A.; Progression of vascular and neural dysfunction in sciatic nerves of Zucker diabetic fatty and Zucker rats. Am J Physiol Endocrinol Metab 2005,289(1),E113-E122","journal-title":"Am J Physiol Endocrinol Metab"},{"key":"ref=145","doi-asserted-by":"publisher","first-page":"1222","DOI":"10.1167\/iovs.13-13794","volume":"55","author":"Davidson E.P.","year":"2014","unstructured":"Davidson E.P.; Coppey L.J.; Kardon R.H.; Yorek M.A.; Differences and similarities in development of corneal nerve damage and peripheral neuropathy and in diet-induced obesity and type 2 diabetic rats. Invest Ophthalmol Vis Sci 2014,55(3),1222-1230","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"ref=146","doi-asserted-by":"publisher","first-page":"307285","DOI":"10.1155\/2015\/307285","volume":"2015","author":"Holmes A.","year":"2015","unstructured":"Holmes A.; Coppey L.J.; Davidson E.P.; Yorek M.A.; Rat models of diet-induced obesity and high fat\/low dose streptozotocin type 2 diabetes: effect of reversal of high fat diet compared to treatment with enalapril or menhaden oil on glucose utilization and neuropathic endpoints. J Diabetes Res 2015,2015,307285","journal-title":"J Diabetes Res"},{"key":"ref=147","doi-asserted-by":"publisher","first-page":"717","DOI":"10.1242\/dmm.028530","volume":"10","author":"Hinder L.M.","year":"2017","unstructured":"Hinder L.M.; O\u2019Brien P.D.; Hayes J.M.; Backus C.; Solway A.P.; Sims-Robinson C.; Feldman E.L.; Dietary reversal of neuropathy in a murine model of prediabetes and metabolic syndrome. Dis Model Mech 2017,10(6),717-725","journal-title":"Dis Model Mech"},{"key":"ref=148","doi-asserted-by":"publisher","first-page":"2598","DOI":"10.2337\/db06-1176","volume":"56","author":"Obrosova I.G.","year":"2007","unstructured":"Obrosova I.G.; Ilnytska O.; Lyzogubov V.V.; Pavlov I.A.; Mashtalir N.; Nadler J.L.; Drel V.R.; High-fat diet induced neuropathy of pre-diabetes and obesity: effects of \u201chealthy\u201d diet and aldose reductase inhibition. Diabetes 2007,56(10),2598-2608","journal-title":"Diabetes"},{"key":"ref=149","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1007\/s11892-015-0682-6","volume":"15","author":"Singleton J.R.","year":"2015","unstructured":"Singleton J.R.; Smith A.G.; Marcus R.L.; Exercise as therapy for diabetic and prediabetic neuropathy. Curr Diab Rep 2015,15(12),120","journal-title":"Curr Diab Rep"},{"key":"ref=150","doi-asserted-by":"publisher","first-page":"372","DOI":"10.3389\/fnins.2016.00372","volume":"10","author":"Cooper M.A.","year":"2016","unstructured":"Cooper M.A.; Kluding P.M.; Wright D.E.; Emerging relationships between exercise, sensory nerves, and neuropathic pain. Front Neurosci 2016,10,372","journal-title":"Front Neurosci"},{"key":"ref=151","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1016\/j.jdiacomp.2012.05.007","volume":"26","author":"Kluding P.M.","year":"2012","unstructured":"Kluding P.M.; Pasnoor M.; Singh R.; Jernigan S.; Farmer K.; Rucker J.; Sharma N.K.; Wright D.E.; The effect of exercise on neuropathic symptoms, nerve function, and cutaneous innervation in people with diabetic peripheral neuropathy. J Diabetes Complications 2012,26(5),424-429","journal-title":"J Diabetes Complications"},{"key":"ref=152","doi-asserted-by":"publisher","first-page":"2658","DOI":"10.1016\/j.pain.2013.07.052","volume":"154","author":"Groover A.L.","year":"2013","unstructured":"Groover A.L.; Ryals J.M.; Guilford B.L.; Wilson N.M.; Christianson J.A.; Wright D.E.; Exercise-mediated improvements in painful neuropathy associated with prediabetes in mice. Pain 2013,154(12),2658-2667","journal-title":"Pain"},{"key":"ref=153","doi-asserted-by":"publisher","first-page":"77","DOI":"10.2174\/138945008783431736","volume":"9","author":"Yorek M.A.","year":"2008","unstructured":"Yorek M.A.; The potential role of angiotensin converting enzyme and vasopeptidase inhibitors in the treatment of diabetic neuropathy. Curr Drug Targets 2008,9(1),77-84","journal-title":"Curr Drug Targets"},{"key":"ref=154","doi-asserted-by":"publisher","first-page":"1130","DOI":"10.1161\/hy1101.092845","volume":"38","author":"de Cavanagh E.M.V.","year":"2001","unstructured":"de Cavanagh E.M.V.; Inserra F.; Toblli J.; Stella I.; Fraga C.G.; Ferder L.; Enalapril attenuates oxidative stress in diabetic rats. Hypertension 2001,38(5),1130-1136","journal-title":"Hypertension"},{"key":"ref=155","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1016\/S0002-9343(02)01241-X","volume":"113","author":"Schiffrin E.L.","year":"2002","unstructured":"Schiffrin E.L.; Vascular and cardiac benefits of angiotensin receptor blockers. Am J Med 2002,113(5),409-418","journal-title":"Am J Med"},{"key":"ref=156","doi-asserted-by":"publisher","first-page":"3274","DOI":"10.2337\/diabetes.51.11.3274","volume":"51","author":"Forbes J.M.","year":"2002","unstructured":"Forbes J.M.; Cooper M.E.; Thallas V.; Burns W.C.; Thomas M.C.; Brammar G.C.; Lee F.; Grant S.L.; Burrell L.M.; Jerums G.; Osicka T.M.; Reduction of the accumulation of advanced glycation end products by ACE inhibition in experimental diabetic nephropathy. Diabetes 2002,51(11),3274-3282","journal-title":"Diabetes"},{"key":"ref=157","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1097\/00004872-200202000-00018","volume":"20","author":"Brosnan M.J.","year":"2002","unstructured":"Brosnan M.J.; Hamilton C.A.; Graham D.; Lygate C.A.; Jardine E.; Dominiczak A.F.; Irbesartan lowers superoxide levels and increases nitric oxide bioavailability in blood vessels from spontaneously hypertensive stroke-prone rats. J Hypertens 2002,20(2),281-286","journal-title":"J Hypertens"},{"key":"ref=158","doi-asserted-by":"publisher","first-page":"1571","DOI":"10.1161\/hc3801.095585","volume":"104","author":"M\u00fcnzel T.","year":"2001","unstructured":"M\u00fcnzel T.; Keaney J.F.; Are ACE inhibitors a \u201cmagic bullet\u201d against oxidative stress? Circulation 2001,104(13),1571-1574","journal-title":"Circulation"},{"key":"ref=159","doi-asserted-by":"publisher","first-page":"406","DOI":"10.1161\/01.RES.0000033523.08033.16","volume":"91","author":"Seshiah P.N.","year":"2002","unstructured":"Seshiah P.N.; Weber D.S.; Rocic P.; Valppu L.; Taniyama Y.; Griendling K.K.; Angiotensin II stimulation of NAD(P)H oxidase activity: upstream mediators. Circ Res 2002,91(5),406-413","journal-title":"Circ Res"},{"key":"ref=160","doi-asserted-by":"publisher","first-page":"1456","DOI":"10.1016\/S0891-5849(01)00727-4","volume":"31","author":"Wingler K.","year":"2001","unstructured":"Wingler K.; W\u00fcnsch S.; Kreutz R.; Rothermund L.; Paul M.; Schmidt H.H.; Upregulation of the vascular NAD(P)H-oxidase isoforms Nox1 and Nox4 by the renin-angiotensin system in vitro and in vivo. Free Radic Biol Med 2001,31(11),1456-1464","journal-title":"Free Radic Biol Med"},{"key":"ref=161","doi-asserted-by":"publisher","first-page":"341","DOI":"10.2337\/diabetes.55.02.06.db05-0885","volume":"55","author":"Coppey L.J.","year":"2006","unstructured":"Coppey L.J.; Davidson E.P.; Rinehart T.W.; Gellett J.S.; Oltman C.L.; Lund D.D.; Yorek M.A.; ACE inhibitor or angiotensin II receptor antagonist attenuates diabetic neuropathy in streptozotocin-induced diabetic rats. Diabetes 2006,55(2),341-348","journal-title":"Diabetes"},{"key":"ref=162","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1038\/oby.2007.19","volume":"16","author":"Oltman C.L.","year":"2008","unstructured":"Oltman C.L.; Davidson E.P.; Coppey L.J.; Kleinschmidt T.L.; Lund D.D.; Yorek M.A.; Attenuation of vascular\/neural dysfunction in Zucker rats treated with enalapril or rosuvastatin. Obesity (Silver Spring) 2008,16(1),82-89","journal-title":"Obesity (Silver Spring)"},{"key":"ref=163","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1007\/BF00400846","volume":"35","author":"Cameron N.E.","year":"1992","unstructured":"Cameron N.E.; Cotter M.A.; Robertson S.; Angiotensin converting enzyme inhibition prevents development of muscle and nerve dysfunction and stimulates angiogenesis in streptozotocin-diabetic rats. Diabetologia 1992,35(1),12-18","journal-title":"Diabetologia"},{"key":"ref=164","doi-asserted-by":"publisher","first-page":"1230","DOI":"10.1007\/BF00400799","volume":"36","author":"Maxfield E.K.","year":"1993","unstructured":"Maxfield E.K.; Cameron N.E.; Cotter M.A.; Dines K.C.; Angiotensin II receptor blockade improves nerve function, modulates nerve blood flow and stimulates endoneurial angiogenesis in streptozotocin-diabetic rats and nerve function. Diabetologia 1993,36(12),1230-1237","journal-title":"Diabetologia"},{"key":"ref=165","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1358\/mf.2001.23.3.627945","volume":"23","author":"Aggarwal M.","year":"2001","unstructured":"Aggarwal M.; Singh J.; Sood S.; Arora B.; Effects of lisinopril on streptozotocin-induced diabetic neuropathy in rats. Methods Find Exp Clin Pharmacol 2001,23(3),131-134","journal-title":"Methods Find Exp Clin Pharmacol"},{"key":"ref=166","doi-asserted-by":"publisher","first-page":"1978","DOI":"10.1016\/S0140-6736(98)02478-7","volume":"352","author":"Malik R.A.","year":"1998","unstructured":"Malik R.A.; Williamson S.; Abbott C.; Carrington A.L.; Iqbal J.; Schady W.; Boulton A.J.; Effect of angiotensin- converting-enzyme (ACE) inhibitor trandolapril on human diabetic neuropathy: randomised double-blind controlled trial. Lancet 1998,352(9145),1978-1981","journal-title":"Lancet"},{"key":"ref=167","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1111\/j.1464-5491.1995.tb00482.x","volume":"12","author":"Reja A.","year":"1995","unstructured":"Reja A.; Tesfaye S.; Harris N.D.; Ward J.D.; Is ACE inhibition with lisinopril helpful in diabetic neuropathy? Diabet Med 1995,12(4),307-309","journal-title":"Diabet Med"},{"key":"ref=168","doi-asserted-by":"publisher","first-page":"1525","DOI":"10.1016\/S0140-6736(01)06584-9","volume":"358","author":"Weber M.A.","year":"2001","unstructured":"Weber M.A.; Vasopeptidase inhibitors. Lancet 2001,358(9292),1525-1532","journal-title":"Lancet"},{"key":"ref=169","doi-asserted-by":"publisher","first-page":"228","DOI":"10.3317\/jraas.2003.037","volume":"4","author":"Ebihara F.","year":"2003","unstructured":"Ebihara F.; Di Marco G.S.; Juliano M.A.; Casarini D.E.; Neutral endopeptidase expression in mesangial cells. J Renin Angiotensin Aldosterone Syst 2003,4(4),228-233","journal-title":"J Renin Angiotensin Aldosterone Syst"},{"key":"ref=170","doi-asserted-by":"publisher","first-page":"S64","DOI":"10.1097\/00005344-199800001-00021","volume":"31","author":"Vatter H.","year":"1998","unstructured":"Vatter H.; Schilling L.; Schmiedek P.; Ehrenreich H.; Evidence for functional endothelin-converting enzyme activity in isolated rat basilar artery: effect of inhibitors. J Cardiovasc Pharmacol 1998,31(Suppl. 1),S64-S67","journal-title":"J Cardiovasc Pharmacol"},{"key":"ref=171","doi-asserted-by":"publisher","first-page":"508","DOI":"10.1097\/01.shk.0000055815.40894.16","volume":"19","author":"Muangman P.","year":"2003","unstructured":"Muangman P.; Spenny M.L.; Tamura R.N.; Gibran N.S.; Fatty acids and glucose increase neutral endopeptidase activity in human microvascular endothelial cells. Shock 2003,19(6),508-512","journal-title":"Shock"},{"key":"ref=172","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1159\/000028304","volume":"59","author":"Edwards R.M.","year":"1999","unstructured":"Edwards R.M.; Pullen M.; Nambi P.; Distribution of neutral endopeptidase activity along the rat and rabbit nephron. Pharmacology 1999,59(1),45-50","journal-title":"Pharmacology"},{"key":"ref=173","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1016\/S0014-2999(98)00038-7","volume":"345","author":"Gonz\u00e1lez W.","year":"1998","unstructured":"Gonz\u00e1lez W.; Soleilhac J.M.; Fourni\u00e9-Zaluski M.C.; Roques B.P.; Michel J.B.; Characterization of neutral endopeptidase in vascular cells, modulation of vasoactive peptide levels. Eur J Pharmacol 1998,345(3),323-331","journal-title":"Eur J Pharmacol"},{"key":"ref=174","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1016\/j.placenta.2003.09.002","volume":"25","author":"Kikkawa F.","year":"2004","unstructured":"Kikkawa F.; Shibata K.; Suzuki T.; Kajiyama H.; Ino K.; Nomura S.; Mizutani S.; Signal pathway involved in increased expression of neutral endopeptidase 24.11 by gonadotropin releasing hormone in choriocarcinoma cells. Placenta 2004,25(2-3),176-183","journal-title":"Placenta"},{"key":"ref=175","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1053\/plac.2002.0820","volume":"23","author":"Suzuki T.","year":"2002","unstructured":"Suzuki T.; Ino K.; Kikkawa F.; Uehara C.; Kajiyama H.; Shibata K.; Mizutani S.; Neutral endopeptidase\/CD10 expression during phorbol ester-induced differentiation of choriocarcinoma cells through the protein kinase C- and extracellular signal-regulated kinase-dependent signalling pathway. Placenta 2002,23(6),475-482","journal-title":"Placenta"},{"key":"ref=176","doi-asserted-by":"publisher","first-page":"355","DOI":"10.2337\/db06-1180","volume":"56","author":"Davidson E.P.","year":"2007","unstructured":"Davidson E.P.; Kleinschmidt T.L.; Oltman C.L.; Lund D.D.; Yorek M.A.; Treatment of streptozotocin-induced diabetic rats with AVE7688, a vasopeptidase inhibitor: effect on vascular and neural disease. Diabetes 2007,56(2),355-362","journal-title":"Diabetes"},{"key":"ref=177","doi-asserted-by":"publisher","first-page":"556","DOI":"10.1016\/j.ejphar.2010.10.047","volume":"650","author":"Oltman C.L.","year":"2011","unstructured":"Oltman C.L.; Davidson E.P.; Coppey L.J.; Kleinschmidt T.L.; Dake B.; Yorek M.A.; Role of the effect of inhibition of neutral endopeptidase on vascular and neural complications in streptozotocin-induced diabetic rats. Eur J Pharmacol 2011,650(2-3),556-562","journal-title":"Eur J Pharmacol"},{"key":"ref=178","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1111\/j.1463-1326.2008.00924.x","volume":"11","author":"Oltman C.L.","year":"2009","unstructured":"Oltman C.L.; Davidson E.P.; Coppey L.J.; Kleinschmidt T.L.; Yorek M.A.; Treatment of Zucker diabetic fatty rats with AVE7688 improves vascular and neural dysfunction. Diabetes Obes Metab 2009,11(3),223-233","journal-title":"Diabetes Obes Metab"},{"key":"ref=179","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1016\/j.ejphar.2011.12.003","volume":"677","author":"Davidson E.P.","year":"2012","unstructured":"Davidson E.P.; Coppey L.J.; Holmes A.; Yorek M.A.; Effect of inhibition of angiotensin converting enzyme and\/or neutral endopeptidase on vascular and neural complications in high fat fed\/low dose streptozotocin-diabetic rats. Eur J Pharmacol 2012,677(1-3),180-187","journal-title":"Eur J Pharmacol"},{"key":"ref=180","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1016\/j.ejphar.2011.07.016","volume":"668","author":"Davidson E.P.","year":"2011","unstructured":"Davidson E.P.; Coppey L.J.; Holmes A.; Dake B.; Yorek M.A.; Effect of treatment of high fat fed\/low dose streptozotocin-diabetic rats with Ilepatril on vascular and neural complications. Eur J Pharmacol 2011,668(3),497-506","journal-title":"Eur J Pharmacol"},{"key":"ref=181","doi-asserted-by":"publisher","first-page":"912327","DOI":"10.1155\/2009\/912327","volume":"2009","author":"Davidson E.P.","year":"2009","unstructured":"Davidson E.P.; Coppey L.J.; Kleinschmidt T.L.; Oltman C.L.; Yorek M.A.; Vascular and neural dysfunctions in obese Zucker rats: effect of AVE7688. Exp Diabetes Res 2009,2009,912327","journal-title":"Exp Diabetes Res"},{"key":"ref=182","doi-asserted-by":"publisher","first-page":"8067","DOI":"10.1167\/iovs.12-10826","volume":"53","author":"Davidson E.P.","year":"2012","unstructured":"Davidson E.P.; Coppey L.J.; Yorek M.A.; Early loss of innervation of cornea epithelium in streptozotocin-induced type 1 diabetic rats: improvement with ilepatril treatment. Invest Ophthalmol Vis Sci 2012,53(13),8067-8074","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"ref=183","doi-asserted-by":"publisher","first-page":"686952","DOI":"10.1155\/2011\/686952","volume":"2011","author":"Davidson E.P.","year":"2011","unstructured":"Davidson E.P.; Coppey L.J.; Dake B.; Yorek M.A.; Effect of treatment of Sprague Dawley rats with AVE7688, enalapril, or candoxatril on diet-induced obesity. J Obes 2011,2011,686952","journal-title":"J Obes"},{"key":"ref=184","doi-asserted-by":"publisher","first-page":"326806","DOI":"10.1155\/2012\/326806","volume":"2012","author":"Coppey L.","year":"2012","unstructured":"Coppey L.; Lu B.; Gerard C.; Yorek M.A.; Effect of inhibition of angiotensin-converting enzyme and\/or neutral endopeptidase on neuropathy in high-fat-fed C57Bl\/6J mice. J Obes 2012,2012,326806","journal-title":"J Obes"},{"key":"ref=185","doi-asserted-by":"publisher","first-page":"1072","DOI":"10.1093\/jnen\/nlw083","volume":"75","author":"Yorek M.S.","year":"2016","unstructured":"Yorek M.S.; Obrosov A.; Lu B.; Gerard C.; Kardon R.H.; Yorek M.A.; Effect of inhibition or deletion of neutral endopeptidase on neuropathic endpoints in high fat fed\/low dose streptozotocin-treated mice. J Neuropathol Exp Neurol 2016,75(11),1072-1080","journal-title":"J Neuropathol Exp Neurol"},{"key":"ref=186","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1007\/164_2016_77","volume":"243","author":"Khder Y.","year":"2017","unstructured":"Khder Y.; Shi V.; McMurray J.J.V.; Lefkowitz M.P.; Sacubitril\/Valsartan (LCZ696) in Heart Failure. Handb Exp Pharmacol 2017,243,133-165","journal-title":"Handb Exp Pharmacol"},{"key":"ref=187","doi-asserted-by":"publisher","first-page":"1616","DOI":"10.2337\/db18-0062","volume":"67","author":"Davidson E.P.","year":"2018","unstructured":"Davidson E.P.; Coppey L.J.; Shevalye H.; Obrosov A.; Yorek M.A.; Vascular and neural complications in type 2 diabetic rats: improvement by sacubitril\/valsartan greater than valsartan alone. Diabetes 2018,67(8),1616-1626","journal-title":"Diabetes"},{"key":"ref=188","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1146\/annurev.nutr.012809.104635","volume":"31","author":"Bazan N.G.","year":"2011","unstructured":"Bazan N.G.; Molina M.F.; Gordon W.C.; Docosahexaenoic acid signalolipidomics in nutrition: significance in aging, neuroinflammation, macular degeneration, Alzheimer\u2019s, and other neurodegenerative diseases. Annu Rev Nutr 2011,31,321-351","journal-title":"Annu Rev Nutr"},{"key":"ref=189","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1016\/j.neuropharm.2016.12.022","volume":"116","author":"Yorek M.S.","year":"2017","unstructured":"Yorek M.S.; Obrosov A.; Shevalye H.; Coppey L.J.; Kardon R.H.; Yorek M.A.; Early vs. late intervention of high fat\/low dose streptozotocin treated C57Bl\/6J mice with enalapril, \u03b1-lipoic acid, menhaden oil or their combination: Effect on diabetic neuropathy related endpoints. Neuropharmacology 2017,116,122-131","journal-title":"Neuropharmacology"},{"key":"ref=190","doi-asserted-by":"publisher","first-page":"725","DOI":"10.1097\/ICO.0000000000001182","volume":"36","author":"Davidson E.P.","year":"2017","unstructured":"Davidson E.P.; Coppey L.J.; Shevalye H.; Obrosov A.; Kardon R.H.; Yorek M.A.; Impaired corneal sensation and nerve loss in type 2 rat model of chronic diabetes is reversible with combination therapy of menhaden oil, \u03b1-lipoic acid, and enalapril. Cornea 2017,36(6),725-731","journal-title":"Cornea"},{"key":"ref=191","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1016\/j.ejphar.2015.08.015","volume":"765","author":"Davidson E.P.","year":"2015","unstructured":"Davidson E.P.; Holmes A.; Coppey L.J.; Yorek M.A.; Effect of combination therapy consisting of enalapril, \u03b1-lipoic acid, and menhaden oil on diabetic neuropathy in a high fat\/low dose streptozotocin treated rat. Eur J Pharmacol 2015,765,258-267","journal-title":"Eur J Pharmacol"},{"key":"ref=192","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1152\/jn.00224.2015","volume":"114","author":"Shevalye H.","year":"2015","unstructured":"Shevalye H.; Yorek M.S.; Coppey L.J.; Holmes A.; Harper M.M.; Kardon R.H.; Yorek M.A.; Effect of enriching the diet with menhaden oil or daily treatment with resolvin D1 on neuropathy in a mouse model of type 2 diabetes. J Neurophysiol 2015,114(1),199-208","journal-title":"J Neurophysiol"},{"key":"ref=193","doi-asserted-by":"publisher","first-page":"453","DOI":"10.4172\/2155-9562.1000453","volume":"8","author":"Obrosov A.","year":"2017","unstructured":"Obrosov A.; Coppey L.J.; Shevalye H.; Yorek M.A.; Effect of fish oil vs. resolvin D1, E1, methyl esters of resolvins D1 or D2 on diabetic peripheral neuropathy. J Neurol Neurophysiol 2017,8(6),453","journal-title":"J Neurol Neurophysiol"},{"key":"ref=194","doi-asserted-by":"publisher","first-page":"5905891","DOI":"10.1155\/2016\/5905891","volume":"2016","author":"Yorek M.S.","year":"2016","unstructured":"Yorek M.S.; Coppey L.J.; Shevalye H.; Obrosov A.; Kardon R.H.; Yorek M.A.; Effect of treatment with salsalate, menhaden oil, combination of salsalate and menhaden oil, or resolvin D1 of C57Bl\/6J type 1 diabetic mouse on neuropathic endpoints. J Nutr Metab 2016,2016,5905891","journal-title":"J Nutr Metab"},{"key":"ref=195","doi-asserted-by":"publisher","first-page":"2967127","DOI":"10.1155\/2018\/2967127","volume":"2018","author":"Davidson E.P.","year":"2018","unstructured":"Davidson E.P.; Coppey L.J.; Shevalye H.; Obrosov A.; Yorek M.A.; Effect of dietary content of menhaden oil with or without salsalate on neuropathic endpoints in high-fat-fed\/low-dose streptozotocin-treated Sprague Dawley rats. J Diabetes Res 2018,2018,2967127","journal-title":"J Diabetes Res"},{"key":"ref=196","doi-asserted-by":"publisher","first-page":"1","DOI":"10.7326\/0003-4819-159-1-201307020-00003","volume":"159","author":"Goldfine A.B.","year":"2013","unstructured":"Goldfine A.B.; Fonseca V.; Jablonski K.A.; Chen Y.D.; Tipton L.; Staten M.A.; Shoelson S.E.; Salicylate (salsalate) in patients with type 2 diabetes: a randomized trial. Ann Intern Med Targeting inflammation using salsalate in type 2 diabetes study team2013,159(1),1-12","journal-title":"Ann Intern Med"},{"key":"ref=197","doi-asserted-by":"publisher","first-page":"346","DOI":"10.7326\/0003-4819-152-6-201003160-00004","volume":"152","author":"Goldfine A.B.","year":"2010","unstructured":"Goldfine A.B.; Fonseca V.; Jablonski K.A.; Pyle L.; Staten M.A.; Shoelson S.E.; The effects of salsalate on glycemic control in patients with type 2 diabetes: a randomized trial. Ann Intern Med TINSAL-T2D (Targeting Inflammation Using Salsalate in Type 2 Diabetes) Study Team2010,152(6),346-357","journal-title":"Ann Intern Med"},{"key":"ref=198","doi-asserted-by":"publisher","first-page":"953","DOI":"10.1517\/13543784.17.6.953","volume":"17","author":"Zhang Y.F.","year":"2008","unstructured":"Zhang Y.F.; Ning G.; Mecobalamin. Expert Opin Investig Drugs 2008,17(6),953-964","journal-title":"Expert Opin Investig Drugs"},{"key":"ref=199","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1016\/j.lfs.2016.07.019","volume":"161","author":"Yao H.","year":"2016","unstructured":"Yao H.; Feng J.; Zheng Q.; Wei Y.; Wang S.; Feng W.; The effects of gliclazide, methylcobalamin, and gliclazide+methylcobalamin combination therapy on diabetic peripheral neuropathy in rats. Life Sci 2016,161,60-68","journal-title":"Life Sci"},{"key":"ref=200","doi-asserted-by":"publisher","first-page":"442","DOI":"10.1111\/j.1365-2362.2010.02430.x","volume":"41","author":"Mizukami H.","year":"2011","unstructured":"Mizukami H.; Ogasawara S.; Yamagishi S.; Takahashi K.; Yagihashi S.; Methylcobalamin effects on diabetic neuropathy and nerve protein kinase C in rats. Eur J Clin Invest 2011,41(4),442-450","journal-title":"Eur J Clin Invest"},{"key":"ref=201","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1179\/147683010X12611460763607","volume":"13","author":"Jian-bo L.","year":"2010","unstructured":"Jian-bo L.; Cheng-ya W.; Jia-wei C.; Xiao-lu L.; Zhen-qing F.; Hong- tai M.; The preventive efficacy of methylcobalamin on rat peripheral neuropathy influenced by diabetes via neural IGF-1 levels. Nutr Neurosci 2010,13(2),79-86","journal-title":"Nutr Neurosci"},{"key":"ref=202","first-page":"11","volume":"43","author":"Han Y.","year":"2018","unstructured":"Han Y.; Wang M.; Shen J.; Zhang Z.; Zhao M.; Huang J.; Chen Y.; Chen Z.; Hu Y.; Wang Y.; Differential efficacy of methylcobalamin and alpha-lipoic acid treatment on symptoms of diabetic peripheral neuropathy. Minerva Endocrinol 2018,43(1),11-18","journal-title":"Minerva Endocrinol"},{"key":"ref=203","doi-asserted-by":"publisher","first-page":"777","DOI":"10.1111\/jdi.12493","volume":"7","author":"Li S.","year":"2016","unstructured":"Li S.; Chen X.; Li Q.; Du J.; Liu Z.; Peng Y.; Xu M.; Li Q.; Lei M.; Wang C.; Zheng S.; Zhang X.; Yu H.; Shi J.; Tao S.; Feng P.; Tian H.; Effects of acetyl-L-carnitine and methylcobalamin for diabetic peripheral neuropathy: A multicenter, randomized, double-blind, controlled trial. J Diabetes Investig 2016,7(5),777-785","journal-title":"J Diabetes Investig"},{"key":"ref=204","doi-asserted-by":"publisher","first-page":"1117","DOI":"10.1089\/acm.2020.0068","volume":"26","author":"Sawangjit R.","year":"2020","unstructured":"Sawangjit R.; Thongphui S.; Chaichompu W.; Phumart P.; Efficacy and safety of mecobalamin on peripheral neuropathy: A systematic review and meta-analysis of randomized controlled trials. J Altern Complement Med 2020,26(12),1117-1129","journal-title":"J Altern Complement Med"},{"key":"ref=205","doi-asserted-by":"publisher","first-page":"135484","DOI":"10.1016\/j.neulet.2020.135484","volume":"741","author":"Peng H-Y.","year":"2021","unstructured":"Peng H-Y.; Gong Y-Y.; Analysis of the effect of probucol-mecobalamin tablets combination on oxidative stress in patients with diabetic peripheral neuropathy. Neurosci Lett 2021,741,135484","journal-title":"Neurosci Lett"},{"key":"ref=206","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1016\/j.diabres.2013.03.033","volume":"101","author":"Xu Q.","year":"2013","unstructured":"Xu Q.; Pan J.; Yu J.; Liu X.; Liu L.; Zuo X.; Wu P.; Deng H.; Zhang J.; Ji A.; Meta-analysis of methylcobalamin alone and in combination with lipoic acid in patients with diabetic peripheral neuropathy. Diabetes Res Clin Pract 2013,101(2),99-105","journal-title":"Diabetes Res Clin Pract"},{"key":"ref=207","doi-asserted-by":"publisher","first-page":"e13020","DOI":"10.1097\/MD.0000000000013020","volume":"97","author":"Jiang D-Q.","year":"2018","unstructured":"Jiang D-Q.; Zhao S-H.; Li M-X.; Jiang L-L.; Wang Y.; Wang Y.; Prostaglandin E1 plus methylcobalamin combination therapy versus prostaglandin E1 monotherapy for patients with diabetic peripheral neuropathy: A meta-analysis of randomized controlled trials. Medicine (Baltimore) 2018,97(44),e13020","journal-title":"Medicine (Baltimore)"},{"key":"ref=208","doi-asserted-by":"publisher","first-page":"534","DOI":"10.1007\/BF00166747","volume":"347","author":"Cotter M.A.","year":"1993","unstructured":"Cotter M.A.; Dines K.C.; Cameron N.E.; Prevention and reversal of motor and sensory peripheral nerve conduction abnormalities in streptozotocin-diabetic rats by the prostacyclin analogue iloprost. Naunyn Schmiedebergs Arch Pharmacol 1993,347(5),534-540","journal-title":"Naunyn Schmiedebergs Arch Pharmacol"},{"key":"ref=209","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1016\/0168-8227(92)90008-F","volume":"18","author":"Ohno A.","year":"1992","unstructured":"Ohno A.; Kanazawa A.; Tanaka A.; Miwa T.; Ito H.; Effect of a prostaglandin I2 derivative (iloprost) on peripheral neuropathy of diabetic rats. Diabetes Res Clin Pract 1992,18(2),123-130","journal-title":"Diabetes Res Clin Pract"},{"key":"ref=210","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1055\/s-0043-112351","volume":"126","author":"Mo F.","year":"2018","unstructured":"Mo F.; Hu G.; Liu W.; He L.; Wang H.; Prostaglandin e1 protects the peripheral nerve in diabetics through preventing vascular permeability changes. Exp Clin Endocrinol Diabetes 2018,126(2),113-122","journal-title":"Exp Clin Endocrinol Diabetes"},{"key":"ref=211","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1016\/0006-291X(88)90509-8","volume":"150","author":"Yasuda H.","year":"1988","unstructured":"Yasuda H.; Sonobe M.; Hatanaka I.; Yamashita M.; Miyamoto Y.; Terada M.; Amenomori M.; Kikkawa R.; Shigeta Y.; Motoyama Y.; A new prostaglandin E1 analogue (TFC-612) prevents a decrease in motor nerve conduction velocity in streptozocin-diabetic rats. Biochem Biophys Res Commun 1988,150(1),225-230","journal-title":"Biochem Biophys Res Commun"},{"key":"ref=212","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1016\/0090-6980(90)90109-9","volume":"40","author":"Suzuki K.","year":"1990","unstructured":"Suzuki K.; Saito N.; Sakata Y.; Toyota T.; Goto Y.; A new prostaglandin E1 analogue (TFC-612) improves the reduction in motor nerve conduction velocity in spontaneously diabetic GK (Goto-Kakizaki) rats. Prostaglandins 1990,40(5),463-471","journal-title":"Prostaglandins"},{"key":"ref=213","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1016\/j.diabres.2003.10.012","volume":"64","author":"Akahori H.","year":"2004","unstructured":"Akahori H.; Takamura T.; Hayakawa T.; Ando H.; Yamashita H.; Kobayashi K.; Prostaglandin E1 in lipid microspheres ameliorates diabetic peripheral neuropathy: clinical usefulness of Semmes-Weinstein monofilaments for evaluating diabetic sensory abnormality. Diabetes Res Clin Pract 2004,64(3),153-159","journal-title":"Diabetes Res Clin Pract"},{"key":"ref=214","first-page":"681","volume":"12","author":"Hoshi K.","year":"1986","unstructured":"Hoshi K.; Mizushima Y.; Kiyokawa S.; Yanagawa A.; Prostaglandin E1 incorporated in lipid microspheres in the treatment of peripheral vascular diseases and diabetic neuropathy. Drugs Exp Clin Res 1986,12(8),681-685","journal-title":"Drugs Exp Clin Res"}],"container-title":["Current Diabetes Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/1573399817666210504101609","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/193121\/article","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/1573399817666210504101609","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,3]],"date-time":"2023-11-03T08:35:10Z","timestamp":1699000510000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.eurekaselect.com\/193121\/article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6]]},"references-count":214,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2022,6]]}},"alternative-id":["LiveAll1"],"URL":"https:\/\/doi.org\/10.2174\/1573399817666210504101609","relation":{},"ISSN":["1573-3998"],"issn-type":[{"value":"1573-3998","type":"print"}],"subject":[],"published":{"date-parts":[[2022,6]]},"assertion":[{"value":"Peer Reviewed","order":0,"name":"review_status","label":"Review Status","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Single blind","order":1,"name":"review_process","label":"Review Process","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Checked with iThenticate","order":0,"name":"screening_status","label":"Screening Status","group":{"name":"plagiarism_screening","label":"Plagiarism Screening"}},{"value":"2020-11-14","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-01-07","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-02-13","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-04-11","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e040521193121"}}